

2.5 Clinical Overview

TABLE OF CONTENTS

TABLE OF CONTENTS	1
TABLE OF FIGURES	2
TABLE OF TABLES	3
2.5.1 PRODUCT DEVELOPMENT RATIONAL	4
2.5.1.1 Pharmacological class	4
2.5.1.2 Information about the condition	4
2.5.1.2.1 Jet Lag Disorder	5
2.5.1.2.2 Shift Work Disorder (SWD)	7
2.5.1.3 Scientific Background	7
2.5.1.4 Clinical Development Programme	8
2.5.1.5 Search Strategy	8
2.5.2 OVERVIEW OF BIOPHARMACEUTICS	10
2.5.2.1 Bioavailability study	10
2.5.2.2 Bioavailability	13
2.5.2.3 Dosage Form/Strength Proportionality	14
2.5.2.4 Differences Between The To-Be-Marketed Formulation And The Formulation(S) Used In Clinical Trials	17
2.5.2.5 Influence Of Food On Exposure	18
2.5.2.6 Influence of Method of Administration	18
2.5.3 OVERVIEW OF CLINICAL PHARMACOLOGY	18
2.5.3.1 Pharmacokinetics	18
2.5.3.1.1 Absorption	20
2.5.3.1.2 Distribution	23
2.5.3.1.3 Metabolism	24
2.5.3.1.4 Excretion and Elimination	25
2.5.3.1.5 Pharmacokinetic studies in special population	26
2.5.3.2 Pharmacodynamics	29
2.5.3.2.1 Circadian Regulation of Sleep	30
2.5.3.2.2 Melatonin and Jet Lag - Mechanism of Action	33
2.5.3.2.3 Melatonin and Shift Work Disorder – Mechanism of Action	33
2.5.3.2.4 PK-PD relationship aspects	33
2.5.4 OVERVIEW OF EFFICACY	36
2.5.4.1 Prevention And Treatment Of Jet Lag	37
2.5.4.1.1 Comparative Studies	37
2.5.4.1.2 Open studies	41
2.5.4.1.3 Reviews and Meta-analyses	41

2.5 Clinical overview

2.5.4.2	Shift Work Disorder (SWD)	45
2.5.4.2.1	Comparative Studies	45
2.5.4.2.2	Reviews and Meta-analyses	48
2.5.4.2.3	Open studies	51
2.5.4.3	Other Uses	51
2.5.4.3.1	Advanced Sleep–Wake Phase Disorder (ASWPD)	52
2.5.4.3.2	Delayed Sleep–Wake Phase Disorder (DSWPD)	52
2.5.4.3.3	Non-24-h Sleep–Wake Rhythm Disorder (N24SWD) or Free-Running Disorder (FRD)	54
2.5.4.3.4	Irregular Sleep–Wake Rhythm (ISWR)	55
2.5.4.3.5	Sleep onset insomnia in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD)	55
2.5.4.3.6	Effect of exogenous melatonin on sleep onset latency, sleep efficiency and total sleep duration	56
2.5.4.4	Other Studies	57
2.5.4.5	Dosage and Administration	60
2.5.5	OVERVIEW OF SAFETY	60
2.5.5.1	Toxicity	60
2.5.5.1.1	Acute Toxicity	61
2.5.5.1.2	Long-term toxicity and Chronic Toxicity	61
2.5.5.1.3	Effect of administered melatonin on suppression of endogenous melatonin secretion	62
2.5.5.1.4	Effect of Melatonin on Cardiovascular System	63
2.5.5.1.5	Pre-implantation development	63
2.5.5.1.6	Mutagenicity	63
2.5.5.1.7	Pregnancy and Lactation	63
2.5.5.2	Drug interactions	65
2.5.5.2.1	Pharmacokinetic drug interactions	65
2.5.5.2.2	Pharmacodynamic drug interactions	66
2.5.6	BENEFITS AND RISKS CONCLUSIONS	66
2.5.6.1	Therapeutic Context	66
2.5.6.1.1	Disease or Condition	66
2.5.6.1.2	Current Therapies	66
2.5.6.2	Benefits	67
2.5.6.3	Risks	67
2.5.6.4	Benefit – Risk Assessment	68
2.5.7	LITERATURE REFERENCES	68

TABLE OF FIGURES

<i>Figure 1 Chemical structure of Melatonin</i>	4
<i>Figure 2 Mean plasma concentration vs time curve for Melatonin 1 mg/1 ml Oral Solution)-Linear plot (on the left) and ln-transformed data (on the right) (Baseline corrected data</i>	12
<i>Figure 3: Dose proportionality of solid and liquid immediate release dosage forms of melatonin (Mean AUC values calculated from data of Table IV.</i>	17
<i>Figure 4 Metabolites derived from melatonin. In humans, melatonin (I) is converted by CYP2C19 to NAS (III) and by CYP1A1, CYP1A2 and CYP1B1 to 6-HMEL (II). Melatonin also undergoes conversion to the ring opened metabolites AFMK (VI), AMK (VII), and to the oxidation products 3-HMEL (V) and 2-OMEL (IV)</i>	24

2.5 Clinical overview

Figure 5 Regulation of melatonin production and receptor function. Neural signals from the SCN follow a multisynaptic pathway to the superior cervical ganglia.	29
Figure 6 Function of Melatonin Receptor subtypes.....	31
Figure 7 Interactions of NE (noradrenalin) released from postganglionic sympathetic fibres with beta-adrenergic receptors in the pinealocyte membrane. This interaction initiates a series of intracellular events, which culminate in a large rise in the acetylation of serotonin to N-acetylserotonin by the enzyme N-acetyltransferase (NAT). Once produced, melatonin is quickly discharged into the capillary bed in the pineal gland and possibly directly into the CSF of the third ventricle.	32
Figure 8 Comparison of Melatonin versus placebo – Outcome I for Global Jet Lag ratings: Eastward flights.	42
Figure 9 Comparison of Melatonin versus placebo – Outcome II for Jet Lag ratings: Westward flights.	42
Figure 10 Comparison of Melatonin versus placebo: Eastward flights, proportion of people with jet lag score > 60.	42
Figure 11 Effects of melatonin on SOL. This forest plot demonstrates that exogenous administration of melatonin lowers sleep onset latency.	44
Figure 12 Effects of melatonin on TST. This forest plot suggests that exogenous administration of melatonin increases total sleep time.	44
Figure 13 Effects of melatonin on SE.	44
Figure 14 Melatonin versus placebo (Outcome I) for sleepiness and sleep disturbances caused by shift work (next day).	50
Figure 15 Melatonin versus placebo (Outcome II) for sleepiness and sleep disturbances caused by shift work (next night).	50
Figure 16 Melatonin versus placebo, Outcome III. Sleep onset latency, next day.	51
Figure 17 (A) Effects of exogenous melatonin on sleep latency. (B) Effects of exogenous melatonin on sleep efficiency. (C) Effects of exogenous melatonin on total sleep duration. Intervals are 95 % confidence intervals for the mean effect.	57

TABLE OF TABLES

Table I Summary of pharmacokinetic parameters estimated for baseline corrected data of Melatonin (N = 16)	11
Table II Summary of pharmacokinetic parameters estimated for baseline uncorrected data of Melatonin (N = 16)	11
Table III Assessment of Pharmacokinetic dose proportionality of Melatonin	15
Table IV: AUC values of solid and liquid immediate release dosage forms of melatonin for doses up to 10 mg.	16
Table V Pharmacokinetic variables after melatonin administration	19
Table VI Reported permeability values of Melatonin	21
Table VII: Pharmacokinetics in relation to pharmacodynamics of melatonin. (*) Acute effects on core body temperature suggest that the half-maximal response occurs in these concentrations.	34
Table VIII: Plasma concentrations produced 1h after melatonin administration of a single immediate release oral formulation compared to study.	35
Table IX Outcomes from Tortorolo et al. Meta-analysis. Moderate certainty: good indication of the likely effect.	43
Table X Effect of Melatonin on Shift Work Disorder.	49

2.5 Clinical overview

2.5.1 PRODUCT DEVELOPMENT RATIONAL

2.5.1.1 PHARMACOLOGICAL CLASS

Melatonin (N-acetyl-5 methoxytryptamine) is a neurohormone that is primarily produced in the pineal gland, located behind the third ventricle in the brain with daily and seasonal rhythms mainly under the control of the circadian oscillator located in the suprachiasmatic nuclei of the hypothalamus (SCN) which have melatonin receptors. The pineal gland is a major component of the endocrine system that allows mammals to respond to the annual changes in photoperiod by adaptive alterations of their physiological state. Melatonin is synthesised in the pineal gland during the dark phase of the light/dark cycle and is rapidly delivered to the body via the systemic circulation. Melatonin is synthesized from tryptophan, which is taken up from the circulation and transformed into serotonin, which is then converted into melatonin by a two-step process involving the sequential activities of two enzymes, serotonin- N -acetyltransferase (NAT), the limiting enzyme in the synthesis of melatonin, and hydroxyindole- O -methyltransferase (HIOMT) [REDACTED]. The mRNAs encoding these enzymes are expressed in the pineal gland with a day/night rhythm.

Melatonin synthesis is initiated by the binding of norepinephrine to adrenergic β 1-receptors, which leads to activation of pineal adenylate cyclase, an increase in cyclic AMP (cAMP) levels, and de novo synthesis of NAT. The cAMP-induced gene transcription repressor (ICER), an isoform of the cAMP-responsive element modulator (CREM), is activated in conjunction with NAT expression and represents a mechanism that limits the nocturnal production of melatonin [REDACTED]. Melatonin synthesis depends upon tryptophan availability, as it is reduced after acute tryptophan depletion [REDACTED] other nutritional factors might also influence melatonin synthesis, for example, folate status [REDACTED] and levels of vitamin B6, a coenzyme in tryptophan decarboxylation that can stimulate melatonin production in prepubertal children, but not in adults [REDACTED].

Melatonin is involved in the entrainment (synchronization) of the circadian rhythms including sleep-wake timing, blood pressure regulation, seasonal reproduction, and many others. Many of its biological effects are produced through activation of melatonin receptors, while others are due to its role as an antioxidant, with a particular role in the protection of nuclear and mitochondrial DNA.




Figure 1 Chemical structure of Melatonin

2.5.1.2 INFORMATION ABOUT THE CONDITION

The sleep- wake cycle may be pathologically affected in different ways. Furthermore, the sleep may also be disturbed by various processes. The disturbances of the sleep-wake cycle are called circadian rhythms disorders and include the jet lag (time zone change) syndrome, shift work sleep disorder, advanced sleep phase syndrome, non-24 h sleep-wake syndrome. In all these, insomnia might appear as a symptom. Chronic insomnia is itself a sleep disorder, in spite of being very complex. Transient difficulty in sleeping is a vastly more common phenomenon than is chronic insomnia. The diagnosis of

2.5 Clinical overview

chronic insomnia is based on the subjective complaint of difficulty in initiating or maintaining sleep or of non-restorative sleep (not feeling well-rested after sleep that is apparently adequate in amount).

Disorders of the sleep-wake schedule or Circadian Rhythm Sleep-Wake Disorders (CRSWDs) are classified under G47.2 of ICD-10 version 2016. The International Classification of Sleep Disorders (ICSD) 3rd Revision, 2014, includes the following conditions under Circadian-Rhythm Disorders ■■■

- Jet lag disorder (ICD-10-CM code: G47.25)
- Shift work disorder (ICD-10-CM code: G47.26)
- Advanced sleep-wake phase disorder (ICD-10-CM code: G47.22)
- Delayed sleep-wake phase disorder (ICD-10-CM code: G47.21)
- Non-24-h sleep-wake rhythm disorder (ICD-10-CM code: G47.24)

All the indications are also included in the draft ICD-11, under section 7A6: Circadian rhythm sleep-wake disorder.

- Circadian rhythm sleep-wake disorder, jet lag type (ICD-11 code: 7A65)
- Circadian rhythm sleep-wake disorder, shift work type (ICD-11 code: 7A64)
- Circadian rhythm sleep-wake disorder, advanced type (ICD-11 code: 7A61)
- Circadian rhythm sleep-wake disorder, delayed type (ICD-11 code: 7A60)
- Circadian rhythm sleep-wake disorder, non-entrained disorder type (ICD-11 code: 7A63)

In all these indications insomnia might appear as a symptom.

Melatonin's two well-established physiological effects - promotion of sleep and entrainment of circadian rhythms - are both mediated by two specific receptor proteins in the brain, and not by the gamma-aminobutyric acid (GABA) receptors through which most hypnotic agents act. This difference probably explains why, unlike the GABA-agonist drugs, which are true "sleeping pills," exogenous melatonin does not suppress rapid eye movement (REM) sleep nor, in general, affect the distribution of sleep stages.

The indications of the product are presented in detail below in 2.5.1.2.1 and 2.5.1.2.2.

2.5.1.2.1 Jet Lag Disorder

Jet lag disorder, also known as time zone disorder, is a common complaint of travellers who fly across a number of time zones ■■■. The symptoms of jet lag are primarily daytime fatigue and sleep disturbance, but also include loss of mental efficiency, weakness and irritability ■■■. Jet lag is caused by desynchronization between the body's circadian system and the new day-night cycle at the traveller's destination. The sleep loss caused by the travel itself often contributes to jet lag. After a flight through six or more time zones most travellers will take 4-6 days to re-establish a normal sleeping pattern and not to feel tired during the day. The severity of jet lag symptoms largely depends on the number of time zones crossed and the direction of travel. They are worse the greater the number of zones crossed. Westbound travel generally causes less disruption, as it is easier to lengthen than to shorten the natural circadian cycle ■■■. These symptoms consist of daytime fatigue, impaired alertness, insomnia, loss of appetite, poor psychomotor coordination, reduced cognitive skills, and depressed mood. Eastbound travel tends to cause difficulties in falling asleep, whereas westbound travel interferes with sleep maintenance ■■■.

2.5 Clinical overview

The disruptive effects of jet lag have been documented at the molecular level of clock genes present in the SCN and peripheral tissues [REDACTED]. Eastbound travel causes phase advances in the body's circadian rhythms, while westbound flight induces phase delays in circadian rhythms. As a consequence jet travellers are forced to synchronize their bodily rhythms; synchronization occurs at a speed of approximately 1.5 h a day after westward flights and approximately 1 h a day after eastward flight irrespective of whether their travel occurs during daytime or night [REDACTED]. Regardless of the direction of air travel, there is also travel fatigue due to factors such as the cramped seats, altered feeding schedule, poor air quality, and inability to sleep [REDACTED]. These factors aggravate the symptoms of jet lag.

A recent review clearly links jet lag with depression. Circadian rhythm disturbances evoked by jet lag are augmented via the intended 'sleep deprivation' the individual imposes upon himself in an attempt to adjust to the local time clock. Jet airline passengers who have travelled both eastward and westward also frequently report that they have experienced depressive symptoms [REDACTED]. The possible links between jet lag and major depressive disorder or psychotic disorder were evaluated based upon the following criteria: (a) absence of major mental problems before the flight, or good remission of existing disorders 1 year or more before the commencement of flight; and (b) the appearance of major affective syndromes or psychotic syndromes during first 7 days after landing. Evidence from epidemiological and electroencephalographic studies additionally implicate sleep disturbances as key factors in the pathogenesis of depressive illness [REDACTED]. The other evidence consistent with the circadian disruption hypothesis of depression comes from the observation that more than 80 % of depressed patients have complaints of sleep disturbances [REDACTED] and demonstrate a variety of polysomnographic abnormalities [REDACTED].

Recent important findings suggest also that jet lag is associated with increased breast cancer risk among female cabin crew [REDACTED]. Since several studies have indicated an increased risk of breast cancer (BC) among female flight attendants (FFAs), two meta-analyses have been performed. The meta-analysis of Liu et al suggest that FFAs have a higher risk of BC compared with the general population [REDACTED]. The same meta-analysis reported that the development of breast cancer has also been linked to the disruption of circadian rhythms which is usually caused by shift work, short sleep duration and exposure to light at night.

These important findings, which link jet lag with breast cancer in female flight attendants and with depression of passengers after changing several time zones confirm that jet lag is associated with impaired functioning and there is a need of minimizing its effects.

A number of pharmacological interventions have been tried to minimize the effects of jet lag.

Treatment for jet lag disorder can begin before travel. Beginning to adjust the circadian clock to the new time zone before travel may be desirable for some travellers, especially if they want to be functioning at their best immediately upon arrival in the new time zone. Studies in the laboratory have shown that starting circadian interventions about 3 days before the day of travel, combining advancing the sleep schedule with appropriately timed bright light and melatonin administration can phase advance the circadian clock by about 2.5 hours and is also beneficial for sleep and well-being. The patient would start by altering their sleep – wake schedule and go to bed an hour earlier each day. They would also aim to get approximately an hour of bright light (four 30-minute pulses of 5000 lux) in the morning, and to take low-dose melatonin (1 – 3 mg) 5 hours before their usual sleep time [REDACTED].

2.5 Clinical overview

The efficacy of melatonin in preventing or reducing jet lag has been reviewed in four systematic reviews [REDACTED] that included numerous randomized controlled trials [REDACTED].

Melatonin, taken close to the target bedtime at the destination (10 pm to midnight), decreased jet-lag from flights crossing five or more time zones [REDACTED]. Daily doses of melatonin between 0.5 and 5 mg are similarly effective, except that people fall asleep faster and sleep better after 5 mg than 0.5 mg. Doses above 5 mg appear to be no more effective. The relative ineffectiveness of 2 mg slow-release melatonin suggests that a short-lived higher peak concentration of melatonin works better. The benefit is likely to be greater the more time zones are crossed, and less for westward flights. In summary, Melatonin is remarkably effective in preventing or reducing jet lag, and occasional short-term use appears to be safe. It should be recommended to adult travellers flying across five or more time zones, particularly in an easterly direction, and especially if they have experienced jet lag on previous journeys. Travelers crossing 2-4 time zones can also use it if need be.

2.5.1.2.2 Shift Work Disorder (SWD)

Shift work sleep disorder (SWD) is a common yet under recognized and undertreated sleep disorder caused by a sleep/wake pattern that is misaligned with the endogenous circadian rhythm [REDACTED], such as that which occurs when an individual works outside typical waking hours. Most commonly associated with night work, SWD can have potentially serious medical, social and economic consequences [REDACTED].

Shift work disorder is characterised by symptoms of insomnia and/or excessive sleepiness associated with the shift work schedule. It is diagnosed by history, but the use of sleep and work logs either alone or in combination with wrist actigraphy for either 2 weeks or for the duration of the shift rotation can be useful. Evening chronotype and sleep disturbance are both associated with depressive symptoms, and in shift workers sleep disturbance is prevalent [REDACTED].

Melatonin for the treatment of shift work disorder has varied results depending on the time of administration. The usual recommendation is to take melatonin before the daytime sleep period owing to the hypnotic effects at this time, resulting in improved sleep.

Shift work has been also reported to be associated with various mental complaints, including anxiety, depression, insomnia and fatigue.

A recent meta-analysis evaluated the effects of pharmacological interventions to reduce sleepiness or to improve alertness at work and decrease sleep disturbances whilst off work, or both, in workers undertaking shift work in their present job and their cost –effectiveness also assessed [REDACTED]. Melatonin (1 to 10 mg) after the night shift may increase sleep length during daytime sleep (mean difference (MD) 24 minutes, 95 % confidence interval (CI) 9.8 to 38.9; seven trials, 263 participants) and night-time sleep (MD 17 minutes, 95 % CI 3.71 to 30.22; three trials, 234 participants) compared to placebo. The authors did not find a dose-response effect. Melatonin may lead to similar sleep latency times as placebo (MD 0.37 minutes, 95 % CI - 1.55 to 2.29; 5 trials, 74 participants). In summary, there is low quality evidence that melatonin improves sleep length after a night shift but not other sleep quality parameters.

2.5.1.3 SCIENTIFIC BACKGROUND

This application has been made under Article 10(a) of Directive 2001/83/EC Well Established Use.

2.5 Clinical overview

Melatonin was first discovered in 1958 [REDACTED] and has subsequently been widely available as both a nutritional supplement and an approved medicine for more than 10 years. Melatonin has been used as a medicinal product in the EU for over 10 years. [REDACTED]

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

The products in Hungary, Finland and Netherlands are indicated for sleep disorders associated with jet lag, shift work or for patients that are registered as blind in a population over 18 years of age.

The current application is made under Article 10(a) of Directive 2001/83/EC, as amended for the short term treatment of circadian rhythm disorders, such as jet lag.

[REDACTED]
[REDACTED] Any data submitted in this overview on alternative conditions to that applied for, is for supportive purposes only on the grounds of safety.

Bio-Melatonin 3 mg filmtabletta, was licensed under Article 10(a) as amended in 2003 for the same indications as that proposed by the applicant. This is clear evidence of well-established use in the EU for more than 10 years. It is also noted that Melatonin 3 mg tablets have recently been approved in Finland for the treatment of Jet Lag in adults, the same indication as being sought by the applicant.

2.5.1.4 CLINICAL DEVELOPMENT PROGRAMME

Since Melatonin oral solution is a medicinal product the active substance of which has a 'well-established medicinal use' within the Community for at least ten years, with recognized efficacy and an acceptable level of safety it is possible to replace results of the pre-clinical and clinical trials by detailed references to published scientific literature (information available in the public domain).

In addition the applicant performed a single-arm PK study, in order to obtain PK data and actually investigate the *in vivo* PK characteristics of the test product oral solution formulation, comparing them to available, extensive literature data.

A comparison between the pharmacokinetic profile of the proposed product and reported data in the literature has been performed [REDACTED]. A synopsis of the findings is presented in section 2.5.2.1 of the clinical overview.

2.5.1.5 SEARCH STRATEGY

[REDACTED]
[REDACTED]

2.5 Clinical overview

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] literature of pharmacological and toxicological interest has been searched by using the current web engines. Pre- and post-marketing studies were taken into account and special emphasis was put to include published literature concerning experience in the form of epidemiological studies and in particular of comparative epidemiological studies. Both favourable and unfavourable documentation is being presented.

Since the number of publications is extremely large, the overview was based on published reviews of the literature. Literature articles cited in the reviews were included in the overview, where possible. Studies performed with any melatonin product are included in this review.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

2.5 Clinical overview

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

2.5.2 OVERVIEW OF BIOPHARMACEUTICS

2.5.2.1 BIOAVAILABILITY STUDY

In order to support the application, the applicant performed a single-arm PK study, in order to obtain PK data and actually investigate the *in vivo* PK characteristics of the test product oral solution formulation, comparing them to available, extensive literature data.

The title of the study was:

An Open Label, Single-Treatment, Single-Period, Single Dose, Bioavailability Study of Melatonin 1 mg/ 1 ml Oral Solution (3 ml Solution) of Lamda Laboratories SA Greece, in Normal, Healthy, Adult, Human Subjects under Fasting Conditions.

The study identification number is [REDACTED]

The purpose of the study was to determine the bioavailability of the Test Product (T): Melatonin 1 mg/1 ml Oral Solution (3 ml Solution, i.e. a single dose of 3 mg) in normal, healthy, adult, human subjects, under fasting conditions and to monitor the safety and tolerability of a single oral dose of the investigational medicinal product (IMP).

It was an open label, single-treatment, single-period, single dose study in 16 healthy, adult, human subjects under fasting conditions.

[REDACTED] The following figures and tables summarize the pharmacokinetic parameters of the Test product.

The following table and figure summarize the pharmacokinetic parameters of the Test product. For baseline corrected data, primary pharmacokinetic parameters are C_{max}, AUC_{0-t} and AUC_{0-inf} secondary parameters are AUC_{0-t}/AUC_{0-inf}, Residual area, T_{max}, Kel and t_{1/2}.

2.5 Clinical overview

Table I Summary of pharmacokinetic parameters estimated for baseline corrected data of Melatonin (N = 16)

Parameters (Units)	Arithmetic Mean \pm SD
	Test Product-T
C_{max} (pg/ml)	8774.235 \pm 4922.787
AUC_{0-t} (pg*hr/ml)	11839.216 \pm 9780.866
AUC_{0-inf} (pg*hr/ml)	11990.474 \pm 9962.512
T_{max} (hrs)	0.406 \pm 0.239
Kel (hrs ⁻¹)	0.915 \pm 0.335
$T_{1/2}$ (hrs)	0.817 \pm 0.195
Residual Area (%)	0.959 \pm 0.743
AUC_{0-t}/AUC_{0-inf} Ratio (%)	99.041 \pm 0.743

Table II Summary of pharmacokinetic parameters estimated for baseline uncorrected data of Melatonin (N = 16)

Parameters (Units)	Arithmetic Mean \pm SD
	Test Product-T
C_{max} (pg/ml)	8774.653 \pm 4923.273
AUC_{0-t} (pg*hr/ml)	11841.709 \pm 9785.532
AUC_{0-inf} (pg*hr/ml)	11993.832 \pm 9968.930
T_{max} (hrs)	0.406 \pm 0.239
Kel (hrs ⁻¹)	0.915 \pm 0.335
$T_{1/2}$ (hrs)	0.818 \pm 0.195
Residual Area (%)	0.961 \pm 0.748
AUC_{0-t}/AUC_{0-inf} Ratio (%)	99.039 \pm 0.748

2.5 Clinical overview




Figure 2 Mean plasma concentration vs time curve for Melatonin 1 mg/1 ml Oral Solution)-Linear plot (on the left) and ln-transformed data (on the right) (Baseline corrected data)

The purpose of this study was to provide pharmacokinetic data of the product under assessment and to allow comparison with data from the public domain. Generally, a PK study is considered a more accurate way to estimate product's performance, as it assesses bioavailability of the active substance from the product by blood measurements, instead of a therapeutic study, setting pharmacodynamics (PD) or clinical endpoints which are highly variable and, regarding the present indications, very difficult to estimate. This approach is further supported also by an extensive investigation of PK and PD characteristics of melatonin immediate release, providing evidence of an existing relationship between the PK and the PD of melatonin in relation to CRSWDs, mainly jet lag. Thus, the Applicant has performed also an extensive literature exercise, aiming to understand and identify the key points of the pharmacokinetics as well as the PK/PD relationship of melatonin, using also relevant PD markers (e.g. phase shifting effects), in order to correlate the concentration – time curve of the product, supported by data, with the desired clinical effects.

Other direct comparisons between liquid and solid formulations of melatonin found in the literature are also included.

As an additional and final step in the bridging strategy, the Applicant has performed an extensive statistical analysis in order to investigate similarity between the Test melatonin oral solution 1 mg/ml and the Reference product utilized in other Applicant-sponsored bioequivalence studies conducted in the past. These BE studies used the well-acknowledged Hungarian reference product (Bio-Melatonin tablets 3 mg/tab) as comparator versus other oral solid Melatonin immediate-release test formulations. These successful BE studies are currently under assessment for the relevant test products (Melatonin 3 mg Tablets and Melatonin 3 mg capsules) within the context of EU submissions. Similarity among the formulations was assessed based on the pharmacokinetic metrics (C_{max} , AUC_{0-t} , AUC_{0-inf} and T_{max}) retrieved in each study and two different approaches were implemented, i.e.:

2.5 Clinical overview

- Statistical techniques including parametric multi-group comparisons (ANOVA), non-parametric multi-group comparisons (Kruskall-Wallis) and post-hoc pairwise comparisons.
- Bioequivalence approach based on the 90% Schuirmann two one sided t-test as also indicated in the *EMA Guideline on the investigation of bioequivalence Doc. Ref.: CPMP/EWP/QWP/1401/98 Rev. 1/ Corr ** (EMA, 2010)*.

Through established statistical techniques it was proved that:

- a) There is **no statistically significant difference** between melatonin 1 mg/ml oral solution and Bio Melatonin 3 mg film-coated tablets Reference product Lot used in the **Tablets study** (based on PK metrics found in 3 × 3 Tablets study) in terms of C_{max} , AUC_{0-t}, AUC_{0-inf} and T_{max} . Statistical significant difference was observed between the test product and the Reference product Lot used in the **Capsules study**.
- b) when a crossover 2 × 2 study was assumed, using bootstrap techniques, a **high chance of reaching bioequivalence** was observed even assuming the high actual within subject variability found for melatonin in the former BE studies. For studies with an adequate number of subjects, the **% probability of declaring BE can be greater than 80 %, in other words higher than the required statistical power of the study**.

Combining all the results obtained within each Section of the report, pharmacokinetic similarity between melatonin 1 mg/ml oral solution and Bio Melatonin 3 mg film-coated tablets, may be supported.

Further to that, the Applicant is of the opinion that the single dose PK study with the proposed formulation, along with a thorough comparison of findings with the PK data from the public domain and other proprietary BE data utilising the acknowledged European Reference Product provides enough information to prove that the proposed formulation has a comparable pharmacokinetic profile with authorized products and by extension to the products used in clinical trials evaluating efficacy and safety.

Overall, these results may support the similar *in vivo* PK performance of test product oral solution to currently authorized products, which in turn reflect the similarity in terms of efficacy and safety. The observed difference in exposure is not expected to be of clinical importance; this fact is supported by the indirect comparison with public domain data as well as through the extensive statistical evaluation of available proprietary data.

In conclusion, in the present case and given that melatonin is recognised as a well-established use compound for the treatment of CRSWDs in the proposed posology, it is considered that the *in vivo* clinical program based on PK data is sufficient to bridge the new formulation in terms of efficacy and safety to the already existing melatonin products administered in the clinical trials of the literature and in the EU clinical practice.

2.5.2.2 BIOAVAILABILITY

The bioavailability of melatonin is discussed in detail in section 2.5.3.1.1 of the present review.

In humans, intravenous melatonin exhibits linear pharmacokinetics over a dosage range of 0.01 µg/kg to 5.0 µg/kg [REDACTED]. However, few studies have examined absolute bioavailability of melatonin in

2.5 Clinical overview

humans. [REDACTED] reported significant rises in plasma melatonin over a 3-hour period following a 50 mg oral dose, with plasma concentrations returning to baseline after 3 hours. In another study, wide ranges in melatonin peak serum concentrations and in the bioavailability of oral melatonin have been reported (mean: 33 %; range: 10 % - 56 %) in 4 normal male volunteers given 20 µg intravenously and 500 µg oral melatonin [REDACTED]. Oral bioavailability in humans with doses of melatonin 80 mg has been also examined [REDACTED]. However, these authors did not administer an intravenous dose and thus could not determine the absolute bioavailability. In a retrospective analysis on multiple studies that used intravenous melatonin or oral preparations (but not both in the same subjects) the estimated oral bioavailability ranges from 3 % to 76 % [REDACTED]. Sex differences in the oral variability of a 0.25 mg dose of melatonin was examined and determined 9 % in men and 17 % in women [REDACTED].

2.5.2.3 DOSAGE FORM/STRENGTH PROPORTIONALITY

The proposed product is available in a single strength of 1 mg/ml as oral solution.

There are only two published trials, which examine the dose proportionality of oral melatonin and deserve further analysis.

[REDACTED] studied the absolute bioavailability of oral melatonin tablets in 12 normal healthy volunteers. Subjects were administered, in a randomized crossover fashion, melatonin 2 mg intravenously and 2 and 4 mg orally. Blood was sampled over approximately eight (estimated) half-lives. Both the 2 and the 4 mg oral dosages showed an absolute bioavailability of approximately 15 %. No difference in serum half-life was seen in any of the study phases. Oral melatonin tablets in dosages of 2 and 4 mg showed poor absolute bioavailability, either due to poor oral absorption, large first-pass metabolism, or a combination of both.

[REDACTED] examined the effects of very low doses of melatonin (0.1 - 10 mg, orally) or placebo, administered at 11:45 h, on sleep latency and duration, mood, performance, oral temperature, and changes in serum melatonin levels in 20 healthy male volunteers. Areas under the time-melatonin concentration curve varied in proportion to the different melatonin doses ingested, and the 0.1- and 0.3-mg doses generated peak serum melatonin levels that were within the normal range of nocturnal melatonin levels in untreated people.

According to the Guideline on the Investigation of Bioequivalence [REDACTED]:

[...] pharmacokinetics is considered to be linear if the difference in dose-adjusted mean AUCs is no more than 25 % when comparing the studied strength (or strength in the planned bioequivalence study) and the strength(s) for which a waiver is considered. In order to assess linearity, the applicant should consider all data available in the public domain with regard to the dose proportionality and review the data critically. Assessment of linearity will consider whether differences in dose-adjusted AUC meet a criterion of ± 25 %.

By applying the above methodology and using the AUC data from the study by [REDACTED], a linear relationship is obtained over the 2 - 4 mg range (Table III). Although there is a trend for a more than proportional increase by increasing the dose, the deviation from linearity does not exceed the ± 25 % criterion. In a similar manner, the same methodology in the AUC data from the study [REDACTED] can be applied [REDACTED]. There is a trend for a more than proportional increase by increasing the dose;

2.5 Clinical overview

however, it does not exceed the threshold of non-proportionality between the usual therapeutic ranges of 1 mg to 10 mg. For lower doses (0.3 mg) there is a borderline non-proportionality.

Table III Assessment of Pharmacokinetic dose proportionality of Melatonin

[REDACTED]				
Dose (mg)	AUC (ng × min/mL)	Dose normalised AUC (ng × min/mL × mg)	Ratio	Linear
4	530.57	132.64	N/A	N/A
2	237.77	118.89	89.63 %	Yes
Dollins et al. [50]				
Dose (mg)	AUC (pg × h/mL)	Dose normalised AUC (pg × h/mL × mg)	Ratio	Linear
10	21000.4	2100.04	N/A	N/A
1	1599	1599.00	76.14 %	Yes
0.3	459.9	1533.00	73.00 %	No

The data [REDACTED] suggest that melatonin has linear kinetics over the range of 1 - 10 mg. This finding is consistent with the SmPC of the centrally approved product, Circadin, which states that kinetics are linear over the range 2 - 8 mg [REDACTED]

The linear pharmacokinetics of melatonin have also been shown in a study [REDACTED] for the dose range 10 - 80 mg [REDACTED]. Additionally, [REDACTED] showed linear pharmacokinetics between 0.4 mg and 4 mg following two different oral surge-sustained release doses in older adults [REDACTED].

These data suggest, also, that a saturable first-pass hepatic metabolism may be responsible for the apparent dose-dependent oral bioavailability.

The existence of an extensive first pass effect for melatonin has been proposed in a study [REDACTED], where the authors found a markedly increased AUC for the ratio of 6-sulfatoxymelatonin to melatonin in plasma after oral as compared with intravenous administration (13 ± 13 vs. 1 ± 1), which can be explained only if one assumes that there was considerable first-pass hepatic extraction after oral administration, giving rise to the conversion of melatonin to 6-sulfatoxymelatonin and thereby decreasing the bioavailability of melatonin. Obviously, the trend towards a more than proportional increase in the AUC, by increasing the dose, can be explained by the saturation of the first pass metabolism. As discussed previously, melatonin is mainly metabolized by the CYP1A2 isoenzyme. For CYP1A2, metabolism of most substrates can be described using the Michaelis-Menten equation, demonstrating saturation kinetics.

The saturable metabolism and subsequent nonlinearity is more obvious in high doses of melatonin. For example, some authors have commented that there is nonlinearity in the pharmacokinetics of oral melatonin with the calculated plasma AUC following a 2.5 mg dose being 0.0014 µg.hr/mL, while that following an 80 mg dose was 0.465 µg.hr/mL, i.e., a 332-fold difference in AUC corresponding to a 32-fold difference in dose [REDACTED]. However, the administration of 80 mg dose falls outside the scope of the proposed product.

A comparison of Literature pharmacokinetic data between solid and liquid immediate release dosage forms of melatonin for doses up to 10 mg does not reveal any differences (Table IV and Figure 3).

2.5 Clinical overview

The superimposed linear regression of melatonin is presented in Figure 3.

Table IV: AUC values of solid and liquid immediate release dosage forms of melatonin for doses up to 10 mg

Reference	Dose (mg)	Form	AUC _{0-t} (pg × h/mL)	Comments
■	0.25	Liquid	14,160.00	Male
	0.25	Liquid	42,084.00	Female
■	2	Liquid	237,180.00	Fasting condition
	2	Liquid	349,560.00	Fed condition
■	10	Liquid	1,800,000.00	-
■	0.3	Solid	27,594.00	-
■	0.3	Solid	26,514.00	20 – 43 years
	0.3	Solid	35,748.00	49 – 73 years
■	1	Solid	95,940.00	-
■	1	Solid	283,200.00	-
	1	Solid	90,516.00	-
■	2	Solid	222,720.00	Fasting condition
	2	Solid	482,160.00	Fed condition
■	2	Solid	237,770.00	-
	3	Solid	530,570.00	-
■	3	Solid	1,690,000.00	-
■	3	Solid	26,911.00	-
■	5	Solid	1,179,230.00	-
■	5	Solid	372,000.00	-fluvaxamine
■	6	Solid	1,180,000.00	premenopausal women
	6	Solid	1,240,000.00	postmenopausal women
■	10	Solid	1,260,024.00	-

2.5 Clinical overview




Figure 3: Dose proportionality of solid and liquid immediate release dosage forms of melatonin (Mean AUC values calculated from data of Table IV).

2.5.2.4 DIFFERENCES BETWEEN THE TO-BE-MARKETED FORMULATION AND THE FORMULATION(S) USED IN CLINICAL TRIALS

The current application includes a bioavailability study of Melatonin 1 mg/ml oral solution. The pharmacokinetic profile of the proposed product is compared to reported values of other melatonin formulations. A link between the proposed product and the published scientific literature has been demonstrated.

Different oral dosage forms of melatonin have been used in the cited literature articles and clinical trials and it is not expected that there are differences between the to-be-marketed formulation and the formulations used in the literature articles. Melatonin oral solution has been studied in a number of articles [REDACTED]; however, the majority of the trials have been conducted with immediate release tablets.

It should be taken into consideration that melatonin has good solubility (aqueous solubility in room temperature is 0.4344 mg/ml) [REDACTED], high permeability (in vitro literature permeability values 105 - 125.5 nm/s and Caco-2 permeability study performed by the applicant, [REDACTED] and linear pharmacokinetics over the 1 mg to 10 mg dosage range [REDACTED]. Therefore, melatonin is a BCS I active substance with linear pharmacokinetics. Data from [REDACTED] literature data are presented in Table VI of Section 2.5.3.1.1.

The pharmacokinetic profiles of immediate release oral dosage form, such as capsules, should be comparable. Data from studies conducted at other strengths can be extrapolated to the 3 mg strength, since the pharmacokinetics are linear (as presented in Table IV and Figure 3). The variable bioavailability of oral melatonin is therefore not related to the differing instant release formulations but is due to the variability in the high first pass metabolism of melatonin.

2.5 Clinical overview

The pharmacokinetic profiles of immediate release oral dosage form, such as oral solution and tablets, should be comparable. Data from studies conducted at other strengths can be extrapolated to the 3 mg strength, since the pharmacokinetics are linear.

2.5.2.5 INFLUENCE OF FOOD ON EXPOSURE

Food deprivation resulted in an increase of tissue and plasma concentrations of Melatonin. Melatonin also acts as an autocrine and paracrine hormone affecting not only epithelium and immune system but also smooth muscle of the digestive tract. Low doses of melatonin improve gastrointestinal transit and affect MMC (Myoelectric Migrating Complex). Pharmacological doses of melatonin delay gastric emptying via mechanisms that involve CCK2 and 5HT3 receptors [REDACTED]. It appears that exogenous melatonin inhibits gastric motility in part by activating sympathetic neurons [REDACTED].

2.5.2.6 INFLUENCE OF METHOD OF ADMINISTRATION

This product is intended to be administered as an oral solution only.

2.5.3 OVERVIEW OF CLINICAL PHARMACOLOGY

2.5.3.1 PHARMACOKINETICS

The pharmacokinetics of melatonin have been reviewed recently [REDACTED]. In clinical studies, melatonin has typically administered orally, sublingually, or intravenously. Until now, the pharmacokinetics of melatonin has primarily been investigated in healthy volunteers following oral and intravenous administration of melatonin, but findings have been inconsistent [REDACTED].

The pharmacokinetic parameters of melatonin are presented in Table V, as described in the review [REDACTED], supplemented with other clinical studies from the public domain.

2.5 Clinical overview

Table V Pharmacokinetic variables after melatonin administration

Study	Dose (mg)	Dosage form	Conditions	C _{max} (pg/ml)	T _{max} (min)	T _{1/2} (min)	AUC (pg × min/ml)	% BA
■	0.25	Oral solution		244.00	23.00	36.00	14160.00	9
	0.25	Oral solution		624.00	23.00	45.00	42084.00	17
■	0.3	IR Capsule		170.00	48.00	–	26514.00	–
	0.3	IR Capsule		255.00	45.00	–	35748.00	
■	0.4	Tablets (IR+CR)		405.00	78.00	108.00	95700.00	–
■	0.5	IR		–	–	47.00	–	33
■	1	Powder		799.00	60.00	–	90516.00	–
	1	IR Capsule		2620.00	60.00	–	283200.00	–
■	2	IR Capsule	Fasting	2800.00	15.00	32.00	222720.00	–
	2	IR Capsule	Fed	6800.00	30.00	–	482160.00	–
	2	MR tablet		–	–	–	–	–
	2	Oral solution	Fasting	3500.00	30.00	–	237180.00	–
	2	Oral solution	Fed	4400.00	30.00	40.00	349560.00	–
■	2	IR Tablet		2175.00	52.00	61.00	237770.00	14
■	3	IR Tablet		5766.00	60.00	65.00	530570.00	16
	3	IR Tablet		11040.00	16.00	94.00	1690000.00	–
	3	Powder		2405.00	40.00	–	26911.00	–
■	3	IR		3561.00	20.00	–	–	–
	4	Tablets (IR+CR)		3999.00	90.00	126.00	727400.00	–
■	5	IR Tablet		25100.00	–	804.00	8480000.00	–
	5	IR Tablet		2180.00	–	564.00	372000.00	–
■	5	IR Tablet		4823.00	30.00	38.00	256885.00	–
■	5	MR tablet		8770.00	167.00	91.00	2300000.00	–
■	6	IR Tablet	Fasting	10618.00	30.00	113.00	–	–
	6	IR Tablet	Fasting	4480.00	60.00	106.00	–	–
■	6	IR Tablet		7900.00	60.00	36.00	684000.00	–
	6	IR Tablet		1800.00	60.00	37.00	138000.00	–
	6	IR Tablet		7200.00	60.00	38.00	654000.00	–
	6	IR Tablet		1700.00	45.00	49.00	144000.00	–
■	6	IR Tablet		16756.00	30.00	46.00	1180000.00	–
	6	IR Tablet		16438.00	53.00	52.00	1240000.00	–
■	10	Oral solution		14974.00	30.00	88.00	1800000.00	–
	10	MR tablet		3820.00	45.00	48.00	507911.00	–
	10	MR tablet		4072.00	210.00	50.00	595400.00	–
■	25	IR Capsule		640.00	90.00	–	102419.00	
	25	IR Capsule		1858.00	90.00		294002.00	–

2.5 Clinical overview

Study	Dose (mg)	Dosage form	Conditions	C _{max} (pg/ml)	T _{max} (min)	T _{1/2} (min)	AUC (pg × min/ml)	% BA
■	80	IR Capsule		-	-	48.00	27870000.00	-
■	100	IR Capsule		101163.00	60.00	41.00	-	-
	240	IR Capsule		-	-	-	31300000.00	-
■	0.0005 mg/kg	IV		-	-	40.00	15054.00	-
	0.0005 mg/kg	IV		-	-	47.00	18006.00	-
	0.0005 mg/kg	IV		-	-	47.00	22614.00	-
	2	IV		96850.00	-	60.00	1630000.00	-
	0.023 mg (250 ml/h)/	IV		124.80	113.40	36.00	15288.00	-
	0.023 mg (250 ml/h)	IV		169.00	110.40	41.00	21846.00	-
■	-	IV		-	4.00	44.00	-	-
■	0.005 mg	IV		-	-	28.00	5400.00	-
	0.02 mg (10 ml/h)	IV		72.10	-	45.00	-	-

2.5.3.1.1 Absorption

According to literature data, the permeability of melatonin is high (Table VI).

Additionally, the applicant undertook a validated in-vitro study to assess the extent of permeability of melatonin across Caco-2 monolayers and efflux from Caco-2 cells. The data showed that Melatonin is highly permeable in the apical to basolateral direction within the Caco-2 cells and when compared with the reference propranolol, it suggests that human intestinal absorption of melatonin would be greater than 90 % (P_{app} $40.3 \times 10^{-6} \text{ cm s}^{-1}$ for A2B, P_{app} $39.9 \times 10^{-6} \text{ cm s}^{-1}$ for B2A). As such, no additional clinical work was performed across different dosage forms, including capsules, due to the high absorption of the melatonin, as the molecule could be considered potentially suitable for a biowaiver under the BCS classification due to it being highly absorbed

The results of the permeability study are presented in Table VI

2.5 Clinical overview

Table VI Reported permeability values of Melatonin

Reference	Dose of Melatonin	$P_{app\ A-B}$	$P_{app\ B-A}$	Efflux ratio ($P_{app\ B-A}/P_{app\ A-B}$)
██████████ ██████████ ██████████	5 μ M	$11.56 \pm 2.00 \times 10^{-6}$ cm/s	$11.58 \pm 1.01 \times 10^{-6}$ cm/s	1.0
██████████ ██████████ ██████████	6.5 μ M	12.5×10^{-6} cm/s	-	-
██████████ ██████████ ██████████ ██████████ ██████████	10 μ M	$40.3 \pm 4.74 \times 10^{-6}$ cm/s	$39.9 \pm 1.30 \times 10^{-6}$ cm/s	0.99
██████████ ██████████ ██████████	50 μ M	$\sim 11.0 \times 10^{-6}$ cm/s	-	-

Usually, molecules with permeability > 10 nm/s in the Caco-2 system (1×10^{-6} cm/s) are classified as highly permeable and have intestinal absorption >90 % ██████████. Other authors suggest a cut-off value of 100 nm/s (or 10×10^{-6} cm/s) [82]. It is reported that the overall ranking of compounds with $P_{app} < 1 \times 10^{-6}$ cm/sec, between $1 - 10 \times 10^{-6}$ cm/sec and $> 10 \times 10^{-6}$ cm/sec can be classified as poorly (0 – 20 %), moderately (20 – 70 %) and well (70 – 100 %) absorbed compounds, respectively ██████████. According to the table above (Table VI), all reported values from literature are $> 10 \times 10^{-6}$ cm/sec for Melatonin indicating that the proposed product has high permeability and therefore all instant release dosage forms would be expected to act in a similar manner.

The absorption and bioavailability of orally administered (exogenous) melatonin in humans has been extensively reported in the literature. Melatonin is rapidly absorbed following oral administration of instant release forms, with T_{max} ranging between 0.25 - 1.0 hours ██████████. A recent study has shown oral melatonin to have a $T_{1/2}$ as low as 6 minutes ██████████.

After taking 3 - 6 mg melatonin, serum C_{max} value is usually at least 10 times higher than the serum concentration of endogenous night-time melatonin.

In studies to ascertain the absolute bioavailability of two strengths of oral melatonin dosing (2 mg and 4 mg), it was found that the absolute bioavailability of melatonin was only approximately 15 %. However, this study showed that there was little between subject variability ██████████. On the other hand, it has been reported in another study that there was significant between subject and gender variability following an oral melatonin solution of 250 μ g ██████████. The absolute oral bioavailability ranged from 1 to 37 % (mean \pm sd values: 8.6 ± 3.6 % for males and 16.8 ± 12.7 % for females, respectively) ██████████. From a retrospective analysis on multiple studies that used intravenous melatonin or oral preparations (but not both in the same subjects) and estimated oral bioavailability to range from 3 to 76 % ██████████.

In a cohort crossover study, the pharmacokinetic parameters of oral and intravenous (i.v.) melatonin in healthy volunteers were investigated after oral or i.v. administration of 10 mg of Melatonin. Mean \pm SD $t_{1/2}$ absorption of oral melatonin was 6.0 ± 3.1 min. Mean T_{max} was 40.8 ± 17.8 min with a median (IQR) C_{max} of 3550.5 (2500.5 – 8057.5) μ g ml⁻¹. Mean $T_{1/2}$ elimination was 53.7 ± 7.0 min. Median

2.5 Clinical overview

absolute bioavailability was 2.5 (1.7 – 4.7 %). Median C_{max} after short i.v. infusion of melatonin was 389,875.0 (174,775.0 – 440,362.5) pg ml⁻¹. Mean $T_{1/2}$ elimination was 39.4 ± 3.6 min, mean V_d 1.2 ± 0.6 l kg⁻¹ and mean CL 0.0218 ± 0.0102 l min⁻¹ kg⁻¹. It was concluded that the bioavailability of oral melatonin was only 3 % [REDACTED]. Exogenous administration of melatonin with a loading dose of 3 mg (as solution through subjects' feeding tube), followed by an hourly dose of 0.5 mg, results in supraphysiological and sustained concentrations of serum melatonin during 12 hours overnight in subjects (in critically ill patients). These findings support that despite a first-pass effect or pharmacological interactions on the enteral absorption of melatonin in critically ill patients, the enteral administration of melatonin is a feasible option with excellent oral bioavailability [REDACTED].

Oral solution of melatonin (10 mg) was also administered in patients, who had undergone a tracheostomy in a randomized double-blind placebo-controlled trial [REDACTED]. Melatonin appeared to be rapidly absorbed from the oral solution and peak concentrations were higher than those reported for comparable doses in healthy individuals [REDACTED]. After oral dosing, the C_{max} is affected by the solubility of melatonin in the formulation, alterations in bioavailability, and clearance. Orally administered melatonin is subject to an extensive 'first-pass effect', with bioavailability reported to be approximately 15 % [REDACTED], although there is high variability due to factors such as cytochrome P450 1A2 (CYP1A2) activity and co administration of interacting drugs [REDACTED].

Melatonin soft capsules showed similar pharmacokinetic parameters compared with the highest dosed of melatonin in powder form but its bioavailability was improved [REDACTED]. Results evidenced that 3 mg of melatonin powder and 1 mg of melatonin soft gel had the same pharmacokinetics, but comparing the absorption, 1 mg melatonin soft gel capsules was faster absorbed than 3 mg melatonin powder. 1 mg of melatonin powder had a low PK and was not well absorbed.

The bioavailability of a new oral spray of melatonin emulsion was compared with a standard oral formulation in healthy subjects [REDACTED]. Data obtained in this study showed that the extent of melatonin absorption after oral spray delivery was 1.8 times that observed after administration of the standard oral tablet; the peak concentration was also significantly higher, 1.5 times the corresponding oral tablet value. The absorption rate expressed as T_{max} and K_a was comparable between the two products.

The bioavailability of long acting melatonin has also been investigated (single dose of melatonin 5 mg capsules). The pharmacokinetic values were C_{max} of 8.768 ± 7.043 ng/mL, T_{max} of 2.7 ± 0.77 h, AUC_{0-t} of 29.814 ± 24.931 h.ng/ mL, $AUC_{0-\infty}$ of 38.537 ± 24.658 h.ng/mL, Cl of 185.293 ± 121.806 L/h, V_d of 451.370 ± 510.039 L and $t_{1/2}$ of 1.509 ± 0.768 h [REDACTED].

Ingestion of 3 mg melatonin caused a marked increase in serum melatonin (3561 ± 1201 pg/ml) within 20 minutes, followed by gradual decrease, but the level still remained higher than the basal level at 240 minutes after ingestion [REDACTED]. The saliva melatonin 60 minutes after the ingestion showed the highest level (1177 ± 403 pg/ml) which was one-third of the plasma level. Elevated melatonin concentrations were observed also with peak values of 435 nmol/l in serum and 241 nmol/l in saliva at 60 minutes after administration of high doses of melatonin (100 mg). Elimination was monophasic following first-order kinetics. The half-lives for serum and saliva melatonin were 41 and 38 minutes, respectively. These results suggested that melatonin is passively secreted into saliva which reflects closely the changes in serum melatonin [REDACTED].

In some high oral dose studies of melatonin, the average absorption half-life for an 80 mg oral dose, when administered to five adult volunteers, was seen to be 24 minutes (range 19 - 29) with peak serum

2.5 Clinical overview

levels 350 - 10,000 times higher than the endogenous night-time peak within 60 - 150 minutes of dosing was observed [REDACTED]. Following the administration to a single adult female of a high oral dose of melatonin (75 mg), peak serum levels of 110 ng/ml approximately 300 minutes post dosing were observed [REDACTED]. However, significant intra -subject variability in exposure parameters has been reported within the literature [REDACTED]. In the case where 2 × 3 mg immediate release tablets were evaluated in pre and post-menopausal healthy female volunteers, the rate of absorption, C_{max} , ranged from 2.827 to 29.289 ng/mL in premenopausal women and from 1.892 to 40.488 ng/mL in postmenopausal women, whereas AUC all values ranged from 2.640 to 39.735 ng·h/mL and 3.072 to 53.132 ng·h/mL for pre- and postmenopausal women, respectively. In this study [REDACTED] high plasma melatonin concentrations were determined also in the case of melatonin formed in oral solution [REDACTED].

Basal serum melatonin levels were studied in conjunction with the administration of a low oral dose of melatonin (0.3 mg) in a group of healthy young adults (mean age 29.2 ± 6.5 years) and in a group of older adults (mean age 60 ± 8.8 years). Serum melatonin levels were measured at 30 minute intervals over a 10-hour period. Time to peak melatonin levels was 48 ± 4.9 minutes in the younger group and 45 ± 6.7 minutes in the older group. Systemic exposure parameters, C_{max} and AUC (mean \pm SD), did not differ significantly between the younger and older groups: 170.2 ± 22.0 pg/ml versus 254.9 ± 45.7 pg/ml and 441.9 ± 21.07 versus 595.8 ± 12.09 pg/ml×h, respectively. Peak melatonin levels following administration of 0.3 mg melatonin were significantly greater than that observed during endogenous secretion: 170.2 versus 101.1 and 254.9 versus 49.4 pg/ml, young and old groups respectively [REDACTED].

A comparison of the endogenous and exogenous melatonin levels was conducted in 23 healthy subjects, 12 young and 11 older adults, of both genders. In the same blood sample, they were able to distinguish endogenous melatonin from exogenously administered D7 melatonin, a molecule in which seven deuterium atoms replace seven hydrogen atoms. All subjects participated in two experiments: one with 250 µg of oral D7 melatonin at midday and, after a washout period of 1 week, one with 250 µg of oral D7 melatonin at midnight. In addition, the young subjects participated in a third study, involving a 23 mg D7 melatonin infusion. Significant gender differences and between subject variability in exposure parameters were reported. Following oral dosing with 250 µg of D7 melatonin, mean \pm sd C_{max} was 243.7 ± 24.6 pg/ml and 623.6 ± 575.1 pg/ml, whereas AUC was 236 ± 07 pg.h/ml and 701 ± 45 pg.h/ml, in males and females respectively. However, there were no significant differences in total body clearance normalised to body weight: 1.27 ± 0.20 L/h/kg and 1.18 ± 0.22 L/h/kg for males and females respectively [REDACTED].

2.5.3.1.2 Distribution

The in vitro plasma protein binding of melatonin is about 60.0 %. Melatonin is mainly bound to albumin, alpha1- acid glycoprotein and high density lipoprotein [REDACTED]. The level of melatonin binding appears to be constant over range of different serum concentrations. Data from the literature indicates that melatonin is distributed in all body fluids and is accessible at all tissues. The mean binding of melatonin to erythrocytes is 49.0 %. Since Melatonin is not strongly or extensively bound to plasma proteins, protein binding effects on pharmacokinetics should not be expected to be significant.

The volume of distribution has been reported to be 35 L [REDACTED].

It has been estimated that the mean steady state volume of distribution ($V_{d,ss}$) in healthy adult volunteers, following an intravenous infusion of D7 melatonin, to be 0.98 L/kg distribution. No gender

2.5 Clinical overview

difference in the $V_{d_{ss}}$ normalized to body weight was observed: 0.99 ± 0.063 L/h/kg and 0.97 ± 0.13 L/h/kg in males and females, respectively [REDACTED].

Distribution from serum to saliva, and passing through the blood-brain barrier is rapid. Concentration in the cerebrospinal fluid is 2.5 times lower than it is in the plasma. Plasma elimination $T_{1/2}$ is usually approximately 45 minutes [REDACTED].

Melatonin reaches all tissues of the body within a very short period. Melatonin half-life is bi-exponential, with a first distribution half-life of 1.4 min and a second of 28.4 minutes [REDACTED]. Melatonin released to the cerebrospinal fluid via the pineal recess attains, in the third ventricle, concentrations up to 20 – 30 times higher than in the blood. These concentrations, however, rapidly diminish with increasing distance from the pineal, thus suggesting that melatonin is taken up by brain tissue [REDACTED]. Bolus i.v. administration of ^{14}C melatonin was shown to rapidly cross the Blood Brain Barrier, interact with brain structures and quickly disappear from the brain, suggesting rapid diffusion and turnover [REDACTED]. Additionally, another human PET study was performed with carbon-11 labelled melatonin in a healthy volunteer (case report). Plasma pharmacokinetics of melatonin and 6-sulfatoxymelatonin were simultaneously determined using radioimmunoassay. Analysis of tracer kinetics showed maximum activity in the brain 8.5 minutes following injection, which was different from the curve observed for the plasma radioactivity (maximum at 3.5 minutes). This result confirmed that melatonin readily crosses the blood brain barrier and that 6-sulfatoxymelatonin is the main plasma metabolite. In this study, the distribution of tracer as a function of time, failed to reveal any specific binding [REDACTED].

2.5.3.1.3 Metabolism

The literature provides information regarding the metabolic fate of melatonin. The metabolic pathway of melatonin is presented in Figure 4.




Figure 4 Metabolites derived from melatonin. In humans, melatonin (I) is converted by CYP2C19 to NAS (III) and by CYP1A1, CYP1A2 and CYP1B1 to 6-HMEL (II). Melatonin also undergoes conversion to the ring opened metabolites AFMK (VI), AMK (VII), and to the oxidation products 3-HMEL (V) and 2-OMEL (IV) [REDACTED]

2.5 Clinical overview

Circulating melatonin is metabolized primarily in the liver where it is first hydroxylated in the C6 position by cytochrome P450 mono-oxygenases (isoenzymes CYP1A2, CYP1A1 and, to a lesser extent, CYP1B1) and thereafter conjugated with sulphate to be excreted as 6-sulfatoxymelatonin (aMT6S); glucuronide conjugation is extremely limited. CYP2C19 and, at lower rates, CYP1A2 also demethylate melatonin to N-acetylserotonin, being otherwise its precursor [REDACTED]. Di and colleagues addressed this issue by measuring the production of the main metabolite 6-hydroxymelatonin sulphate following oral and intravenous administration.

The metabolism in extrahepatic tissues exhibits substantial differences. Tissues of neural origin, including the pineal gland and retina, contain melatonin-deacetylating enzymes, which are either specific melatonin deacetylases or less specific aryl acylamidases; as eserine-sensitive acetylcholinesterase has an aryl acylamidase side activity, melatonin can be deacetylated to 5-methoxytryptamine in any tissue carrying this enzyme. Melatonin can be metabolized non-enzymatically in all cells, and also extracellularly, by free radicals and a few other oxidants. It is converted into cyclic 3-hydroxymelatonin when it directly scavenges two hydroxyl radicals [REDACTED]. From one of the studies reviewed, it appears that repeated dose administration does not alter the metabolic profile of melatonin.

In the study [REDACTED], a markedly increased area under the curve (AUC) for the ratio of 6-sulfatoxymelatonin to melatonin in plasma after oral as compared with intravenous administration (13 ± 13 vs. 1 ± 1) was found, which can be explained only if one assumes that there was considerable first-pass hepatic extraction after oral administration, giving rise to the conversion of melatonin to 6-sulfatoxymelatonin and thereby decreasing the bioavailability of melatonin [REDACTED]. The study confirmed that there was a clear inverse relation between the AUC ratio and bioavailability after oral melatonin administration, confirming that the low bioavailability was a consequence of hepatic first-pass extraction, which converts melatonin to its metabolite before it enters the systemic circulation.

2.5.3.1.3.1 *Active metabolites*

A substantial fraction of melatonin is metabolized to kynuramine derivatives in the brain. This is of interest as the antioxidant and anti-inflammatory properties of melatonin are shared by these metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and, with considerably higher efficacy, N1-acetyl-5-methoxykynuramine (AMK). AFMK is produced by numerous non-enzymatic and enzymatic mechanisms; its formation by myeloperoxidase appears to be important in quantitative terms [REDACTED].

2.5.3.1.4 **Excretion and Elimination**

The primary metabolite of melatonin, 6-sulphatoxymelatonin, accounts for around 90 % of the dose excreted in the urine [REDACTED]. The other main metabolite results from melatonin O-demethylation, yielding N-acetylserotonin [REDACTED]. Approximately 2 % of the exogenous metabolite is excreted in an unchanged form. No figures are provided as to the extent of urine excretion of the secondary metabolite, mainly the glucuronide conjugate of 6-hydroxymelatonin. A $T_{1/2}$ elimination of approximately 45 min has been documented in several studies in a wide range of doses, up to 100 mg intravenously. This parameter may also be described by first-order elimination kinetics, and is independent of dose and route of administration. Additionally, [REDACTED] approximately 1 % of blood melatonin is excreted in the urine without being metabolized. The authors concluded in a positive correlation between AUC_{MLT} and 6-OH-MLT-S in the urine [REDACTED]. In another study, it is reported that 6-Sulphatoxymelatonin (aMT6s) is the major urinary metabolite of melatonin [REDACTED] and its

2.5 Clinical overview

measurement in urine appears to provide a robust, simple and reliable assessment of melatonin secretion. Over 90 % of the administered radioactivity (β - ^{14}C melatonin) was recovered in the first 24 h urine sample and the remainder in the next 24 h [REDACTED].

Following intravenous infusion of 23 mcg, total body clearance in healthy males and females was 1.27 ± 0.20 L/h/kg and 1.18 ± 0.222 L/h/kg respectively [REDACTED]. The half-life of melatonin following single intravenous and oral doses in healthy volunteers has been reported to be approximately 1 hour [REDACTED]. Elsewhere, the elimination half-life has been reported as 43.6 minutes following intravenous administration in human subjects [REDACTED]. It has also been determined that the half-life following an intravenous infusion to be 36.0 and 41.4 minutes in males and females respectively, and after oral dosing, 36.0 and 45.0 minutes, respectively [REDACTED].

[REDACTED] used a population pharmacokinetic turnover and surge-function model for describing the circadian disposition of melatonin in healthy male subjects. A median acrophase at 04:00 was observed, although their model estimated typical value was at 02:00. The elimination half-life was estimated to be 2.7 hours, longer than 0.5 to 1.0 hours reported after exogenous intravenous and oral melatonin administration to healthy adults. This difference may reflect the continuous formation and release of melatonin while hormone synthesised earlier was undergoing elimination from the bloodstream, thereby leading to an underestimation of the terminal phase slope [REDACTED].

Pharmacokinetic parameters of melatonin after i.v. infusion, i.v. bolus or oral administration are presented in Table V.

2.5.3.1.5 Pharmacokinetic studies in special population

2.5.3.1.5.1 *Paediatrics*

To determine whether melatonin pharmacokinetics change during puberty, [REDACTED] infused melatonin i.v. in 9 pre-pubertal (8.4 ± 1.5 years), 8 pubertal (12.9 ± 1.7 years), and 16 adult subjects and measured melatonin in serum and saliva, and 6-hydroxymelatonin sulfate in urine [REDACTED]. A pilot study of 3 adult males showed dose linearity, absence of saturation kinetics, and unaltered metabolism and urinary excretion for doses of 0.1 mcg/kg, 0.5 mcg/kg, and 5.0 mcg/kg. All other subjects received 0.5 mcg/kg melatonin. The results of pharmacokinetic parameters calculated from serum melatonin showed no significant gender differences in adults. However, developmental differences were significant between pre-pubertal children and adults for terminal elimination rate constant (1.08 ± 0.25 h $^{-1}$ versus 0.89 ± 0.11 h $^{-1}$), elimination half-life (0.67 ± 0.12 h vs. 0.79 ± 0.10 h), and area under the concentration-time curve [250.9 ± 91.8 vs. 376.9 ± 154.3 (pg/mL) h, respectively]. At all time-points melatonin levels were higher in serum than in saliva, and the ratio between serum and salivary melatonin varied up to 55-fold within and between individuals. Results based on salivary melatonin showed significant differences between pre-pubertal children and adults for the terminal elimination rate constant (1.90 ± 0.95 h $^{-1}$ versus 1.06 ± 0.28 h $^{-1}$). The described group differences in pharmacokinetic parameters suggest that pre-pubertal children metabolize melatonin faster than adults.

2.5.3.1.5.2 *Young adults and Elderly*

Serum melatonin concentrations decrease in old age and it has been reported that in healthy elderly people suffering from insomnia, urinary 6-S-MT was significantly lower and its onset and peak time delayed, in comparison to age-matched controls with no sleep disorders. Similarly, in elderly females,

2.5 Clinical overview

6-sulfatoxy melatonin levels were found to be significantly lower in poor compared to good sleepers [REDACTED]

In a study [REDACTED], the magnitude and duration of melatonin secretion were measured over a period of 25 hours with pharmacokinetic studies employing administration of D7 melatonin at midday and at midnight in two separate studies and two groups of subjects, 12 young (26.7 ± 4.4 years) and 11 older men and women (70.0 ± 3.3 years). For all subjects, endogenous melatonin concentrations were lower than 0.5 pg/ml between 10 am and 6 pm. A rapid rise was observed for all subjects and steady state was reached in, 3 - 4 h (3 or 4 half-lives). Secretion started at $20:10 \pm 50$ min ($19:15 - 21:25$) and $20:40 \pm 40$ min ($19:50 - 21:45$) in young men and women, respectively. Offset of secretion was at $04:05 \pm 50$ min (range, 03:05 - 05:25) and at $04:20 \pm 35$ min (range, 03:35 - 05:10) for men and women, respectively. No significant gender difference in duration of secretion (7.9 ± 0.8 h and 7.6 ± 0.8 h), C_{max} (54.7 ± 23.1 and 54.2 ± 26.4 pg/ml) and AUC (375.5 ± 178.6 and 349.7 ± 174.8 pg.h/ml) was observed [REDACTED]. The values of terminal half-life, $T_{1/2} = 1.2 \pm 0.3$ and 1.1 ± 0.5 h, were determined by regression of the terminal portion of the log-plasma concentration-time profile and showed no significant gender difference. There was also no significant gender difference in the amount of nocturnal secretion normalized to body weight of subjects: 0.48 ± 0.23 and 0.40 ± 0.19 $\mu\text{g}/\text{kg}$ in men and women, respectively. Steady state melatonin concentrations were equal to 47.2 ± 20.4 pg/ml (range, 17.0 - 85.7) and 46.3 ± 25.5 pg/ml (range, 18.7 - 91.5) in men and women, respectively, with no significant gender difference.

In a randomized, double-blind, placebo-controlled study of low (0.4 mg) and high (4 mg) dose melatonin (25 % immediate release + 75 % controlled release) in 27 older adults with insomnia complaints and low endogenous melatonin levels, the pharmacokinetic properties of melatonin were determined. The time to maximum level (1.3 hours versus 1.5 hours), elimination half-life (1.8 hours versus 2.1 hours) and apparent total clearance (379 l/hr versus 478 l/hr) did not differ significantly between the low and high dose arms, respectively. The maximum concentration was 405 ± 93 pg/ml for the low dose arm and 3999 ± 700 pg/ml for the high dose arm, both of which are substantially higher than physiologic melatonin levels for this age group. Additionally, subjects in the high dose arm maintained melatonin levels > 50 pg/ml for an average of 10 hours, which could result in elevated melatonin levels beyond the typical sleep period. The authors concluded in a linear pharmacokinetic behavior of melatonin in this older group of patients [REDACTED].

2.5.3.1.5.3 *Impaired Renal Function*

The melatonin status of patients in end-stage Chronic Renal Failure (CRF) was evaluated by the determination of daytime plasma melatonin levels and by the investigation of the circadian rhythmicity of melatonin secretion [REDACTED]. A significant increase in plasma melatonin concentration was found in all CRF patient groups investigated, i.e. CRF patients on conservative treatment (CT; n = 48), CRF patients on maintenance haemodialysis treatment (HD; n = 39) and CRF patients on peritoneal dialysis (PD; n = 32). Successful transplantation led to a marked reduction in plasma melatonin levels. The circadian rhythm of melatonin secretion also appeared to be suppressed in CRF as the nocturnal secretory surge was absent in all HD patients and in 80 % of the post-transplantation patients studied. Another study on patients with end stage renal disease receiving haemodialysis, showed that melatonin plasma concentrations were not affected by the process suggesting that haemodialysis is unable to eliminate melatonin [REDACTED]. Thus, it appears that renal insufficiency affects melatonin elimination and is not compensated by haemodialysis.

2.5 Clinical overview

2.5.3.1.5.4 *Impaired Hepatic Function*

Plasma melatonin levels have been studied in seven patients with cirrhosis and seven age-, sex-, and education-matched controls. It was found that patients with cirrhosis and subclinical hepatic encephalopathy had abnormal plasma melatonin pattern compared with healthy controls [REDACTED]. Three variables of the melatonin profile were analysed. Time of onset of melatonin secretion was significantly displaced from 7:50 p.m. \pm 26 min to 9:30 p.m. \pm 13 min ($p = 0.013$). Time of peak plasma melatonin levels was significantly displaced from 12:36 a.m. \pm 33 min to 5:36 a.m. \pm 29 min. In addition, significant increases in absolute melatonin levels were seen during daytime and night time hours ($P < 0.05$ at every measurement between 2:30 a.m. and 10:00 a.m.).

In a subsequent study, urinary 6-sulfatoxymelatonin levels in 21 hospitalized cirrhotic patients with normal renal function was measured (14 men and 7 women; median age, 50 years [range, 29 to 80 years]; Child class A, 7 patients; class B, 11 patients; class C, 3 patients) and in 9 healthy persons (3 men and 7 women; median age, 49 years [range, 32 to 69 years]). Sixteen had alcoholic liver disease, 2 had hepatitis C, and 1 each had primary biliary cirrhosis and Wilson disease. Two patients had signs of clinically overt hepatic encephalopathy [REDACTED]. Eight-hour urine excretion (10:00 p.m. to 6:00 a.m.) was assayed for 6-sulfatoxymelatonin and finally cirrhotic patients had a significantly decreased concentration (mean \pm SE, 19.01 ± 2.76 ng/mL compared with 39.2 ± 5.41 ; $p = 0.001$) and total excretion (median, 8.28 mg [range, 0.85 to 28.1 mg] compared with 12.21 mg [range, 9.12 to 29.04 mg]; $P < 0.05$) of 6-sulfatoxymelatonin, compared with controls. Urine volumes were similar in the two groups. No correlation to child class or liver function measures was seen. These findings indicate that the elevated plasma melatonin levels seen in cirrhotic patients are at least partly due to impaired hepatic catabolism.

2.5.3.1.5.5 *Critically ill patients*

Critically ill patients exhibit reduced melatonin secretion, both in nocturnal peaks and basal daytime levels. Its early enteral absorption and daily pharmacokinetics were determined in two cohort of six high-risk patients in the prospective trial [REDACTED]. Following enteral administration, pharmacological levels were already reached in 5 minutes with a serum peak after 16 minutes half-absorption time: 3 min and 17 sec). The maximum serum level observed was 11040 pg/mL and the disappearance rate indicated a half-elimination time of 1 hour and 34 minutes. Serum melatonin levels decreased significantly after midnight; pharmacological levels were maintained up to 10 hours following administration. Critically ill patients exhibited reduced melatonin secretion and despite the critical illness, the oral bioavailability was satisfactory (serum levels after oral administration showed basically unchanged intestinal absorption, while disappearance rate was slower than reported in other studies in healthy volunteers [REDACTED]).

2.5.3.1.5.6 *Pregnancy*

Melatonin has protective actions on both the foetus and the mother during pregnancy. It can easily cross the placenta to enter the foetal circulation leading the photoperiodic information to the foetus [REDACTED]. During pregnancy there is a high metabolic demand for oxygen, which leads to a higher ROS production and, consequently, oxidative stress. The placenta is a major source of oxidative stress because it is rich in poly-unsaturated fatty acids. Spontaneous abortion and recurrent pregnancy loss have been associated with systemic oxidative stress [REDACTED]. Due to melatonin level increase, during gestation in normal pregnant humans, reducing the oxidative stress and abortion rate, melatonin has been suggested as a potential molecule to be administered throughout compromised pregnancy such

2.5 Clinical overview

as in pre-eclampsia and foetal undernutrition, two entities associated with oxidative stress. In preeclampsia, lipid peroxide levels in maternal blood and placental tissue are increased and total antioxidant activities are lowered. Melatonin levels were found to be decreased in severe pre-eclampsia [REDACTED]. Some recent evidence has suggested supplements of melatonin to prevent pre-eclampsia in humans [REDACTED].

2.5.3.2 PHARMACODYNAMICS

A melatonin receptor nomenclature was recently proposed by the International Union of Pharmacology (IUPHAR) [REDACTED]. Two subtypes, MT₁ and MT₂, of mammalian melatonin receptors have been cloned. Both subtypes are members of the seven-transmembrane G protein-coupled receptor family.

Physiologically, melatonin secretion increases soon after the onset of darkness, peaks at 2 - 4 am and diminishes during the second half life of the night [REDACTED].




Figure 5 Regulation of melatonin production and receptor function. Neural signals from the SCN follow a multisynaptic pathway to the superior cervical ganglia.

Melatonin binds to two receptors co-localized in the SCN (Supra-Chiasmatic Nuclei) (MT₁ and MT₂). While the specific functional roles of each receptor are not yet defined, there is some evidence that the MT₂ receptor may be more important in the phase-shifting actions of melatonin and the MT₁ receptor in sleep-related actions [REDACTED]. The MT₁ receptor is coupled to different G proteins that mediate adenylyl-cyclase inhibition and phospholipase C β activation, while the MT₂ receptor is also coupled to inhibition of adenylyl-cyclase and, additionally, inhibits the soluble guanylyl cyclase pathway. MT₁ and MT₂ polymorphisms have been found in humans and may be associated with sleep disorders [REDACTED]. A binding protein originally thought to represent a third membrane receptor (MT₃) turned out to be the primarily cytosolic enzyme quinone reductase 2 (QR2).

Some effects of melatonin cannot be explained by membrane receptors or radical scavenging. Melatonin appears to be the natural ligand for the orphan nuclear hormone receptor superfamily RZR/ROR. Melatonin nuclear receptors are involved in the immunomodulator effect of melatonin [REDACTED].

Melatonin may also promote sleepiness via its effects on peripheral vessels. It induces a vasodilatation itself leading in turn to an increase of skin temperature which constitutes an effective signal for

2.5 Clinical overview

sleepiness [REDACTED]. This last effect may be the prominent mechanism of action of exogenous melatonin [REDACTED].

The difference between the physiological and pharmacological effects of melatonin is not always clear, but is based upon the dose, and not the duration, of the hormone message. It is accepted that a "physiological" dose provides plasma melatonin levels of the same order of magnitude as a nocturnal peak (equal to, or lower than, 100 pg/ml or 400 pM) [REDACTED].

2.5.3.2.1 Circadian Regulation of Sleep

The neurons of the major circadian clock, the Suprachiasmatic Nuclei (SCN) of the hypothalamus, are normally active during the day and slow down at night. The activation of SCN neurons has an inhibitory effect on the pineal gland, defining a nocturnal pattern of melatonin secretion. If SCN neurons are activated at night, e.g., by environmental light perceived by the retina, melatonin production declines. Melatonin, in turn, can acutely attenuate the activity of SCN. This melatonin action is likely to support a normal decline in the activity of the SCN at night, further promoting melatonin secretion and contributing to an overall increase in the amplitude of circadian body rhythms. A temporal and functional interplay between melatonin and SCN, and their response to environmental light, promote a temporal alignment of multiple circadian body rhythms with each other (internal synchronization) and with the periodic changes in the environment (external synchronization).

Different mechanisms of action have been reported for melatonin. Its antioxidant and radical scavenging properties are well known and widely described in the scientific literature [REDACTED]. Melatonin is also the endogenous agonist of two G-protein-coupled membrane receptors, named MT1 and MT2 [REDACTED] as presented in Figure 5, displaying binding affinities in the nanomolar range. Its lipophilic nature favours membrane crossing and interaction with intracellular targets. The so-called MT3 binding site is an enzyme belonging to the quinone reductase family; it has lower affinity for melatonin than MT1 and MT2 receptors, and may contribute to the antioxidant properties of melatonin [REDACTED]. Moreover, melatonin has been found to interact with other cellular targets, such as calmodulin [REDACTED]. MT1 and MT2 receptors are negatively coupled to adenylate cyclase, and they can also interact with other intracellular second messengers [REDACTED]. In humans, they are expressed in different areas of the CNS, such as the SCN, cerebellum, hippocampus, substantia nigra and nucleus accumbens [REDACTED]. They have also been found in peripheral tissues, such as retina, coronary arteries, immune cells, intestine and epithelial cells [REDACTED]. The differential role of the two receptor subtypes has been elucidated only partially. Activation of MT1 receptors inhibits neuronal firing within the SCN [REDACTED] and inhibits the release of hormones, such as prolactin [REDACTED] as seen in Figure 5, while activation of MT2 receptors induces splenocyte proliferation, vasodilatation of coronary arteries and inhibits dopamine release in the retina [REDACTED]. Experiments on rat caudal artery demonstrated the involvement of the MT1 receptor in the vasoconstrictive effect of melatonin and of the MT2 receptor in vasodilatation [REDACTED].

2.5 Clinical overview




	mt₁	mt₂	MT₃
Nomenclature			
Other Names	Mel _{1a} ML _{1A}	Mel _{1b} ML _{1B}	ML ₂
Affinity (K_D)	45 pM	140 pM	0.3-2 nM
Pharmacology	MLT >> NAS	MLT >> NAS	MLT = NAS
Selective Agonists	---	---	N-Acetyl 5HT 5-MCA-NAT
Selective Antagonists	---	4P-ADOT 4P-PDOT	PRAZOSIN

Figure 6 Function of Melatonin Receptor subtypes

The human melatonin receptor subtypes show 60 % homology at the amino acid level and distinct pharmacological profiles of partial agonists and antagonists. The use of cell lines expressing the human MT1 and MT2 melatonin receptors has led to the discovery of subtype selective analogues.

In addition to an acute inhibition of SCN activity, melatonin administration can also produce a shift in the circadian phase of SCN activity, either advancing or delaying its onset. The direction of the phase-shift depends on the time of melatonin treatment, i.e., administration of melatonin in the late afternoon can advance the circadian clock, while early-morning treatment can cause a phase delay [REDACTED]. Studies conducted in vitro suggest that a chronobiological effect of melatonin, i.e., the induction of circadian phase shift, is likely to be explained by its direct effect on SCN neurons via specific, most likely, MT2 receptor [REDACTED]. Although the magnitude of the melatonin-induced phase shifts can vary between the species, the overall phenomenon appears to be well conserved. Such phase shifts in the circadian oscillation of SCN activity may change the physiological and behavioural rhythmicity of the entire organism, including the sleep-wake cycle, and can significantly affect the sleep quality in both nocturnal and diurnal species. In humans suffering from circadian sleep disorders, daily melatonin treatment can help to reinforce the circadian synchronization with the environment and entrain the physiological rhythms to a 24-hour cycle TUL [REDACTED].

Depending on the tissue and species, melatonin can activate different second messenger cascades acting on the same receptor subtype. By using recombinant melatonin receptors, it has been shown that the predominant cellular effect of the melatonin is the inhibition of forskolin-stimulated cAMP accumulation in the SCN and PT [REDACTED]. This effect of melatonin is pertussis toxin sensitive, indicating coupling of the receptor to a Gi protein [REDACTED]. Thus, the classical effect of MT1 and MT2 receptors are primarily coupled, in an inhibitory manner, to the AC → cAMP → PKA signaling pathway, via a pertussis toxin sensitive Gi protein [REDACTED], as described in Figure 7. The decrease in cAMP production reduces the uptake of linoleic acid, an essential and major fatty acid, by specific fatty acid transporters. Co-precipitation experiments showed that the MT1 receptor is coupled to different G proteins that mediate AC inhibition and phospholipase Cβ activation. Thus, MT1 receptor activation leads to activation of a large variety of G proteins including Gα2, Gα3, and Gαq/11 proteins [REDACTED], and Gαs, Gαz, and Gα16 [REDACTED]. Moreover, activation of MT1 receptors leads to activation of phospholipase Cβ (PLC-β), with a concomitant increase of inositol-(1,4,5)-triphosphate (IP3), cytosolic Ca²⁺ and 1,2-diacylglycerol [REDACTED]. In addition. Activated MT1 receptors inhibit cAMP responsive element binding protein (CREB) phosphorylation, a nuclear transcriptional activator of cAMP-sensitive gene factor [REDACTED], and also inhibit the formation of immediate early gene products, c-Fos and Jun B [REDACTED].

2.5 Clinical overview




Figure 7 Interactions of NE (noradrenalin) released from postganglionic sympathetic fibres with beta-adrenergic receptors in the pinealocyte membrane. This interaction initiates a series of intracellular events, which culminate in a large rise in the acetylation of serotonin to N-acetylserotonin by the enzyme N-acetyltransferase (NAT). Once produced, melatonin is quickly discharged into the capillary bed in the pineal gland and possibly directly into the CSF of the third ventricle [REDACTED]

The functional significance of this differential G protein coupling has further deciphered that Gi2 and Gi3 proteins mediate AC inhibition through a pertussis toxin–insensitive Gq/11 protein and are coupled to phospholipase C β activity in cell lines (HEK293, Cos-7, CHO cells) through stably expressing MT1 receptors [REDACTED]. Parallel signalling processes are observed through other G proteins, including G0, Gz, or G16. This stimulatory effect is independent of an interaction with Gi or Gs proteins and associated with a calcium–calmodulin (CaM) signal transduction pathway and c-Jun N-terminal kinase activation [REDACTED]. Stimulation of recombinant human MT1 receptors potentiates also the prostaglandin F_{2a}-induced release of arachidonate and hydrolysis of phosphoinositide [REDACTED]. MT1 receptors induce a transient elevation in cytosolic calcium ion concentration and in inositol phosphate accumulation, are associated further with increased phosphorylation of mitogen-activated protein kinase (MEK1/2) and extracellular signal–regulated kinase (ERK1/2) and regulate other ion fluxes and specific ion channels, such as increase in potassium conductance by activating inward rectifier potassium channels (Kir3/GIRK or Ca²⁺ activated K⁺ channel, BKca), and potentiate prostaglandin F_{2a}- and ATP-mediated stimulation of PLC activity [REDACTED].

Expression of human MT1 and MT2 receptors in COS-7 cells demonstrates that activation of these receptors stimulates c-Jun N-terminal Kinase (JNK) activity via pertussis toxin–sensitive and insensitive G proteins [REDACTED].

The expression of MT1 receptors in the human SCN decreases with advancing age as well as in the late stages of Alzheimer's disease. Sleep disruptions, nightly restlessness and circadian rhythm disturbances seen in the elderly and in patients with Alzheimer's disease may be due to alterations of MT1 receptor expression found in the SCN [REDACTED].

A third mechanism of the biological effects of melatonin is through MT3 receptor, which is identified with lower melatonin affinity, very rapid ligand association/dissociation kinetics and widely distributed in various tissues of the body.

In circadian rhythm disorders, as jet lag and shift work disorder, melatonin can advance or delay the body clock and it may also have a hypnotic action due to its temperature lowering abilities.

2.5 Clinical overview

The usefulness of melatonin in jet lag could be due to either its chronobiotic effects, its hypnotic effects or both [REDACTED]. In the case of shift work disorder, it is suggested that melatonin administered prior to retiring for night-time sleep may reset the pattern and facilitate sleep in individuals experiencing insomnia due to varying work schedules [REDACTED].

2.5.3.2.2 Melatonin and Jet Lag - Mechanism of Action

The mechanism of melatonin action is not known for certain. As described, melatonin can advance or delay the body clock according to when it is ingested. However it may also have a hypnotic action due to its temperature lowering abilities that may be attributed to its actions on peripheral blood vessels, i.e. melatonin acts separately as a chronobiotic and hypnotic. If melatonin is to be used for its temperature lowering, hypnotic effect it should be taken at approximately 2000 hours at the new local time, irrespective of the flight that had been undertaken. However, if melatonin is to be used as a chronobiotic it should be taken at a certain time (according to the direction of travel and number of time zones crossed) to phase advance or phase delay endogenous rhythms. The usefulness of melatonin in jet lag could be due to either its chronobiotic effects, its hypnotic effects or both [REDACTED].

2.5.3.2.3 Melatonin and Shift Work Disorder – Mechanism of Action

During periods of night-shift work, the circadian pattern of melatonin secretion is advanced, resulting in maximum secretion during daylight and facilitation of daytime sleep. The altered pattern of secretion may result in a decrease in night-time sleep duration and an increase in number of daytime naps when the worker is not working nights. It has been suggested that melatonin use prior to retiring for night-time sleep may reset the pattern and facilitate sleep in individuals experiencing insomnia due to varying work schedules [REDACTED].

2.5.3.2.4 PK-PD relationship aspects

Based on its mechanism of action as a chronobiotic, the response of the body to melatonin follows a phase-response curve (PRC), so that morning administration causes a delay, while evening administration causes an advance on circadian rhythms. This PRC is about 12 h out of phase with the PRC to light which causes a phase advance in the morning and a phase delay in the evening [REDACTED]. The shift of the circadian rhythm induced as depicted in the PRC in a PD marker that may be considered indicative of melatonin's efficacy in the treatment of jet lag. Indeed, there were many studies in the literature investigating the PRC produced after administration of exogenous melatonin at a specific time and after subtraction of the baseline PRC estimated before administration [REDACTED]. This is also supported by the fact, that, the observed differences on the effects of melatonin in relation to administration time, are not due to differences in pharmacokinetics, but probably in a difference in the already existing melatonin concentration and in the phase of circadian human rhythm [REDACTED].

Daytime administration of 0.1 to 0.3 mg generated peak serum melatonin concentrations within the normal nocturnal ranges of untreated people. These and higher doses produce measurable hypnotic effects independently of the circadian time signal synchronizing action. This finding underlines the importance of administration time in relation to the desired effects. Unlike the sustained blood levels observed from endogenous release, oral doses produce a rapid increase in blood concentration followed by a rapid decrease [REDACTED].

[REDACTED] to investigate the potential dose-relationship when administering exogenous melatonin by evaluating the phase shift and the change in core body

2.5 Clinical overview

temperature that it induces. When the investigators administered 0.5 and 3.0 mg melatonin doses at the same clock times over four pulses (days), they observed a 3.0- and 3.9-h phase advances, respectively. As for the shifting in the temperature minimum to occur within afternoon/evening was achieved by 73 % of the volunteers receiving 3 mg of melatonin and 56 % of the volunteers receiving 0.5 mg melatonin [REDACTED]. Another study [REDACTED], managed to establish a dose-response relationship with immediate release 0.5 - 5.0 mg melatonin, having as responses the phase shift induced, sleep onset, sleep quality and the core body temperature (Table VII). In this study, the investigators administered in 6 healthy volunteers a non-conventional oral dosage form consisting of a milk suspension of a corn-oil melatonin preparation [REDACTED].

Table VII: Pharmacokinetics in relation to pharmacodynamics of melatonin [REDACTED]. (*) Acute effects on core body temperature suggest that the half-maximal response occurs in these concentrations [REDACTED].

Dose (mg)	Time of administration (h)	T _{max} (min)	C _{max} (pg/ml)	T _{1/2} (min)	C _{plasma} at maximum response (*) (pmol/L)	Phase advance (h)
0.05	17:00	30	118	64.8	~430	0.36
0.50		60	1327	42.6	~4300	0.69
5.00		30	18495	70.2		1.43

[REDACTED] proved that both 3 mg and 0.5 mg of melatonin induced a mean phase advance and a mean phase delay of the same magnitude about 1.5 h [REDACTED]. Also in the study of [REDACTED], 0.5 mg and 5.0 mg of immediate release melatonin were practically equally effective in alleviating jet lag, while 2 mg melatonin sustained release was less effective [REDACTED]. Pharmacological doses of melatonin (5 mg) induce larger advances of the endogenous melatonin rhythm and therefore faster resynchronization of the sleep-wake cycle than physiological doses (0.5 mg). Furthermore, the bioavailability of melatonin, is very poor, and at lower doses, sufficiently high blood levels of melatonin may not be achieved. Independent of the dose, immediate release preparations were more effective than prolonged release formulations. Slow-release preparations, which mimic the endogenous melatonin profile, were useful for melatonin substitution in elderly insomniacs, but for the therapy of chronobiological disorders, it would appear that a rapid increase of melatonin levels is necessary to synchronize the suprachiasmatic nucleus (SCN) and to initiate sleep [REDACTED]. The better results obtained with immediate release formulations compared to sustained release were also proved in another study administering 3 mg of melatonin as an immediate release formulation, as a sustained release formulation and as a formulation consisting of 25 % immediate release and 75 % of sustained release [REDACTED].

In a study proving the efficacy of melatonin in resynchronization after a 7h-eastward travel, salivary melatonin was measured before travel as control and then volunteers were divided into three groups (placebo, 5mg IR melatonin, 300 mg SR caffeine). Saliva melatonin control levels ranged between 0.14 - 409 pg/ml with a mean value of 30 pg/ml. The placebo group had saliva melatonin concentrations significantly higher starting three days after flight. Both the melatonin and the caffeine group maintained the saliva melatonin, and thus plasma levels near to control levels almost for all days of the experiment (30 pg/ml measured at 07:00 am) [REDACTED].

Moreover, it is interesting to note that in the study [REDACTED] the salivary samples contained > 300 pg/ml melatonin 1h hour after 3 mg melatonin administration [REDACTED]. This is in accordance with previous pharmacokinetic findings proving that melatonin's maximum levels and thus maximum effects are noticed about one hour after administration. Thus, the plasma levels achieved

2.5 Clinical overview

with an immediate release dosage form about 1 h after administration, may be indicative of its efficacy (Table VIII).

Table VIII: Plasma concentrations produced 1h after melatonin administration of a single immediate release oral formulation [REDACTED] compared to study [REDACTED]

Dose (mg)	Plasma levels (pg/ml)
0.1	50
0.3	120
1.0	400
2.0	1900
3.0 (study [REDACTED])	4840
10.0	6300
80.0	25800

Probably due to the inherent variability of circadian rhythms among humans, no direct dose-response relationship, especially in terms of jet lag management or phase shifting was explicitly established [REDACTED]. However, a nonlinear dose response in the melatonin PRC with only about 40 % increased amplitude for a 500 % larger dose has been demonstrated [REDACTED]. Based on dose-response studies, setting as response sleep onset it was proved that melatonin receptors are saturated at levels above > 200 pg/mL, as doses form 0.3 mg to 10.0 mg produced effects of similar magnitude [REDACTED].

Daytime sleepiness which is also the most common adverse reaction of melatonin when administered for jet lag was dose dependent. In the study [REDACTED], melatonin's administration induced dose-dependently decrements in alertness and performance efficiency [REDACTED]. Since the most common used methodologies to evaluate the effects of melatonin on prevention and treatment of jet lag and treatment of shift work disorder include self-rated Visual Analogue Scale (VAS), Profile of Mood States (POMS), actigraphy, sleep diaries and questionnaires, the correlation of concentration – time curves of melatonin and desired clinical effects is difficult. Most of the clinical studies evaluate the fatigue, the daytime tiredness, the onset of sleep at destination the onset and quality of sleep, the psychological functioning and the duration of return to normal. On the other hand, melatonin displays a high inter-individual variability in the parameter of serum levels and the correlation of different doses of melatonin with the clinical effect is therefore difficult. The study [REDACTED] demonstrated a dose-effect relationship of melatonin with induced acrophase shift, by administering 0.05 mg, 0.5 mg and 5 mg of melatonin and recording advances of the melatonin acrophase from less than 1 hour to 1.5 hour. Additionally, acute dose-dependent temperature suppression and decrements in alertness and performance efficiency were induced after melatonin administration.

Also, [REDACTED] 0.5 mg and 3.0 mg of melatonin induced the same magnitude of phase advance (about 1h), while the 3.0-dose caused sleepiness and performance decrement during the hours between melatonin ingestion and bedtimes [REDACTED]. In a study of 1 h sleep schedule advance combined with both early morning light and afternoon melatonin treatment (0.5 or 3 mg), it was shown that the addition of melatonin caused a significantly greater phase advance of 2.5 h. Although there was no significant difference in phase shift between the 2 doses, there was a slight difference in the sleepiness they produced. The 3.0 mg dose made subjects sleepier, whereas sleepiness after the 0.5 mg dose was almost identical to that, observed after placebo [REDACTED].

Even if its sleep-inducing effects might help to sleep at the new bedtime, by imposition of darkness [REDACTED], this effect does not seem to have a significant clinical advantage for the jet lag indication

2.5 Clinical overview

██████████. Therefore, most of articles reviewed agree that the use of low doses is encouraged, as <1 mg is sufficient to shift human rhythms and as higher doses (3 – 80 mg) are soporific, inducing daytime sleepiness ██████████. It has been proved that even doses as low as 0.5 mg are sufficient to promote phase advances or phase delays, dependently on the time of administration and thus is effective for the prevention, treatment and/or alleviation of jet lag ██████████. High doses of melatonin (5 – 80 mg) are soporific, as melatonin mainly exerts its hypnotic effect ██████████ ██████████. Therefore, in general, many reviews and reports, based on subjective measures of jet lag suggested that melatonin is effective at doses of 2 - 5 mg taken shortly before bedtime ██████████ in an immediate release formulation ██████████.

Resuming the aforementioned findings, it seems that doses that produce plasma levels over 200 – 400 pg/ml (produced with approximately 0.5 - 1.0 mg immediate release melatonin), are deemed efficient and safe, when the time of administration is the appropriate for the treatment of jet lag. Thus, low, immediate release doses administered shortly before bedtime in the new time zone are hypothesized from a PD point of view to be beneficial in alleviating perceived jet lag effects.

This exercise, resulting in significant information regarding the performance of melatonin's immediate release products, is used in order to identify the appropriate bridging data needed for such an application.

2.5.4 OVERVIEW OF EFFICACY

There are two general approaches to address the symptoms of jet lag and shift work disorder. The first is to accelerate realignment of the circadian system with the external environment and the second is to treat the symptoms of insomnia and excessive sleepiness. Multimodal approaches are typically needed and should be tailored to the individual, because the severity of symptoms and timing of treatments depends on the direction of travel and number of times zones crossed or the type of work schedule ██████████. Phase shifting, or resetting the circadian clock, is achieved by timed light – dark exposure and or melatonin administration.

The inclusion criteria of the studies were assessed for methodological quality as well as for melatonin effectiveness. Most of the clinical studies included in this clinical overview, compare melatonin's effect on circadian rhythm disorders versus placebo. Participants completed sleep logs, symptoms questionnaires and POMS (Profile of Mood States) before melatonin administration. These studies examine also the evidence for the effectiveness of different dosage regimen. Additionally, in most of the studies immediate release oral dosages forms of melatonin were used.

In the studies that are presented in the following sections several methods have been used to evaluate the efficacy of melatonin such as self-rated VAS (Visual Analog Scale), polysomnographic recordings, sleep-log diaries, individual actograms and wrist Actigraphy, SSS (Stanford Sleepiness Scale), POMS (Profile of Mood States), MEMS (Medication Event Monitoring System), sleep EEG, Electrooculography (EOG), Electromyography (EMG) and several other questionnaires ██████████ ██████████.

Most of the clinical studies evaluate the fatigue, the daytime tiredness, the onset of sleep at destination the onset and quality of sleep, the psychological functioning and the duration of return to normal. On the other hand, melatonin displays a high inter-individual variability in the parameter of serum levels and the correlation of different doses of melatonin with the clinical effect is therefore difficult. The study ██████████ demonstrated a dose-effect relationship of melatonin with induced

2.5 Clinical overview

acrophase shift, by administering 0.05 mg, 0.5 mg and 5 mg of melatonin and recording advances of the melatonin acrophase from less than 1 hour to 1.5 hour. Additionally, acute dose-dependent temperature suppression and decrements in alertness and performance efficiency were induced after melatonin administration [REDACTED].

According to the Guideline on medicinal products for the treatment of insomnia [EMA/CHMP/16274/2009 previously (EMEA/16274/2009) Rev. 1] [REDACTED], two complementary types of trials are required to demonstrate efficacy in the clinical development programme:

- (1) Trials documenting effects on objective (usually self-rating) endpoints in the “natural” setting and
- (2) Trials documenting effects on objective endpoints (polysomnography).

The following clinical efficacy criteria should be evaluated as a minimum acceptable standard:

- Sleep onset latency
- Sleep continuity
- Sleep duration
- Feeling of restorative sleep and quality of sleep
- Subsequent daytime functioning in the natural setting

In the following studies, at least one of these outcomes is assessed.

In all studies included in the clinical overview [REDACTED], the effect of melatonin on jet lag patients or patients suffering from work shift disorder, is described following the abovementioned criteria.

2.5.4.1 PREVENTION AND TREATMENT OF JET LAG

Melatonin’s utility in the management of jet lag has been the subject of many studies. When making travel plans, jet particularly over a distance of five or more time zones, travellers should take melatonin on the day of travel at the projected night time hour in the new time zone and on subsequent days in the new time zone. In the case of flights that cross seven to eight time zones, it may be beneficial to initiate melatonin one to three days before the intended day of travel in order to better acclimate the traveller to the new time zone [REDACTED]. Melatonin should be administered in the mid-afternoon of the departure city (at approximately 3 p.m.) to mimic an approximate bedtime in the destination city (at approximately 9 p.m.). On the day of arrival, travellers should avoid evening light and should take melatonin at the new bedtime in the destination city. Circadian rhythms should advance by one to two hours each day with time zone changes, and melatonin can be taken one to two hours earlier each day until the traveller has adjusted.

2.5.4.1.1 Comparative Studies

The impact of various dosage forms of melatonin and placebo on jet lag symptoms was evaluated [REDACTED] in a double-blind, randomized trial [REDACTED]. The efficacy of melatonin was evaluated by electronic medication event monitoring system and questionnaires. The study showed that 5 mg melatonin significantly alleviated the jet lag syndrome, improved self-rated sleep quality, shortened

2.5 Clinical overview

sleep latency and reduced fatigue. Additionally, melatonin proved more effective than a slow-release formulation (2 mg controlled release formulation). Lower (0.5 mg) physiological doses were almost as effective as pharmacological doses (5.0 mg). Only the hypnotic properties, such as sleep latency, were significantly greater with melatonin 5.0 mg. A dose-effect relationship with melatonin has also been demonstrated in artificially induced acrophase shift, in a double-blind placebo-controlled crossover study. While single 5 mg doses of exogenous melatonin administered in the late afternoon induced an advance of the melatonin acrophase of approximately 1.5 hour, melatonin doses of 0.5 mg and 0.05 mg resulted in advances of less than 1 hour [REDACTED]. Melatonin treatment induced acute, dose-dependent temperature suppression and decrements in alertness and performance efficiency. These observations suggest that pharmacological doses of melatonin (5 mg) induce larger advances of the endogenous melatonin rhythm and therefore faster resynchronization of the sleep-wake cycle than physiological doses (10.5 mg). A significant dose-response relationship existed between the dose of oral melatonin, the magnitude of temperature suppression and the degree of advance phase shift in the endogenous melatonin and temperature rhythms, suggesting that acute changes in body temperature by melatonin may be a primary event in phase-shifting mechanisms. Furthermore, the bioavailability of melatonin, which fluctuates between 10 % and 56 %, is very poor, and at lower doses, sufficiently high blood levels of melatonin may not be [REDACTED].

Beaumont et al studied the effects of slow-release caffeine (SRC) and melatonin (Mlt) on sleep and daytime sleepiness after a seven-time zone eastbound flight. In a double-blind, randomized, placebo-controlled study, each of three groups of nine subjects was given either 300 mg SRC on recovery day 1 (D1) to D5 (0800) or 5 mg Mlt on pre-flight D-1 (1700), flight day D0 (1600), and from D1 to D3 (2300), or placebo (Pbo) at the same times. Night-time sleep was evaluated by polysomnography and daytime sleepiness from measurements of sleep latencies and continuous wrist actigraphy. Compared with baseline, they found a significant rebound of slow-wave sleep on night 1 (N1) to N2 under Pbo and Mlt and a significant decrease in rapid eye movement sleep on N1 (Pbo) and N1–N3 (Mlt). Sleepiness was objectively increased under Pbo (D1 – D6) and Mlt (D1 – D3). SRC reduced sleepiness but also tended to affect sleep quality until the last drug day [REDACTED].

[REDACTED] et al examined the effects of low doses of melatonin (0.1 – 10 mg orally) or placebo on sleep latency and duration, mood, performance, oral temperature and changes in serum melatonin levels in healthy volunteers. Administration of a small melatonin dose (0.1 - 0.3 mg, p.o.) during the daytime, which raises serum melatonin concentrations to within the normal nocturnal range, or of slightly higher doses (1.0 - 10 mg, p.o.) was shown to cause hypnotic effects relative to placebo. These effects include a decrease in objective and self-estimated sleep-onset latency, an increase in sleep duration, and sleepiness upon waking. Self-reported feelings of sleepiness and fatigue were increased and feelings of vigour diminished. Oral temperature and the number of correct responses on the Wilkinson auditory vigilance task were found to decrease significantly after ingestion of 1.0 and 10 mg of melatonin. These results are similar to those reported after ingestion of benzodiazepines and suggest that melatonin may find use as a hypnotic drug [REDACTED]. These data are consistent with other observations, with reported decrease in daytime latency of sleep onset in subjects given 1.7 mg of melatonin and increased feelings of sleepiness after 9 hours of melatonin administration.

The efficacy of oral melatonin in alleviating jet lag in flight crew after a series of international flight has been investigated [REDACTED]. A double-blind placebo-controlled trial resulted in reduced feelings of let lag and a more rapid recovery of sleep and energy levels. The timing of melatonin dose seems also crucial. In aircrew returning from a duty that includes a large number of time-zone changes over 1 week or more, melatonin taken a few days prior to returning home results in a worse

2.5 Clinical overview

adjustment. One explanation for this finding is that it may be caused by the natural circadian rhythm being so disrupted at this end of the duty that melatonin started before arrival does not re-entrain unless it is taken in the context of a stable day-night cycle. Another possible explanation comes from recent work that suggests melatonin shifts circadian rhythms according to a phase-response curve. In another study [REDACTED], subjects taking melatonin reported less jet lag and took less time to recover from their shift across 12 time zones [REDACTED]. Subjects reported also that they were less tired during the day and required less time to establish a normal sleeping pattern and reach their normal level of energy. The lack of adverse side effects in subjects taking melatonin suggests that it is well tolerated at the dose used.

In another double-blind cross-over study, melatonin (2 mg) or placebo, was administered daily for 4 weeks to 12 volunteers [REDACTED]. The most consistent effect observed was an increase in tiredness during the evening when taking melatonin. The first recorded episode of excessive sleepiness occurred 4 days after beginning treatment. In the group as a whole, evening tiredness (19.00 h) was first significantly different from placebo ratings on day 5 after beginning treatment. A circadian covariation of fatigue and urinary melatonin from which they infer that their results are compatible with melatonin being involved in the regulation of the human sleep-wake cycle. Melatonin treatment was generally well tolerated, albeit with a few reports of poor mood in the early evening. The dose given, while small, must nevertheless be considered as pharmacological. The same group determined the plasma concentrations of melatonin in healthy subjects after ingestion of three different oral preparations [REDACTED] (a dose of 2 mg was given as either a gelatine capsule, a solution or as a slow-release tablet).

[REDACTED] examined melatonin's ability to transduce light-dark information, its hypnotic effects in man and its low toxicity in a double blind study [REDACTED]. Subjects took a daily dose of melatonin (5 mg in gelatine lactose) or placebo. Subjects were asked to rate their jet lag on a 10 cm visual analogue scale from 0 (insignificant) to 100 (very bad). Jet lag was deliberately not defined as its nature and severity vary from person to person but it was considered to be present at scores of 50 or above. Fisher's exact test for small sample sizes indicated that jet lag was significantly less severe among subjects treated with melatonin. In another study of the same group, it has been reported that in sensitive individuals melatonin can induce rapid drowsiness after late afternoon ingestion and hence detection of treatment [REDACTED]. Most subjects reported no significant jet lag. The rate of resynchronization of aMT6s rhythms was consistent with that previously reported for melatonin [REDACTED].

The effects of oral melatonin in alleviating jet lag and its effects on subjects who had flown from London to Eastern Australia, 10 time-zones to the east, have been also examined. Melatonin (5 mg/day⁻¹) or placebo capsules were administered to 14 experimental and 17 control subjects, respectively, in a double-blind study; the time of administration was in accord with the current consensus for maximizing its hypnotic effect [REDACTED]. The greatest amount of adjustment occurred in the first 3 days. There was also a significant time-of-day effect, jet-lag being higher in the afternoon and evening than in the morning and at noon. The authors hypothesized that melatonin works only in those individuals in whom fatigue is high and motivation is low; in the current study, all subjects were motivated to be active in the new environment, and many were determined to 'throw off' any negative effects due to sleep loss, for example.

On the other hand, a new rating scale for measuring severity of jet lag was validated [REDACTED] in a randomized, double-blind trial of placebo and three alternative regimens of melatonin (5.0 mg at bedtime, 0.5 mg at bedtime, and 0.5 mg taken on a shifting schedule) for jet lag [REDACTED]. Despite the finding of no group differences, the validity of the measures (summary jet lag item and total jet lag

2.5 Clinical overview

score) is supported by their ability to demonstrate gradual improvement in the severity of jet lag over time.

The effects of 5 mg melatonin in comparison with placebo when administered at 12:00, 17:00, 19:00 and 21:00 hours were investigated [REDACTED] in double-blind study. Eighteen young adults were studied with the 7/13 ultrashort sleep-wake paradigm after an overnight sleep deprivation. After each administration, melatonin significantly increased sleep propensity, the spectral power in the theta, delta and spindles bands, and subjective sleepiness. It significantly decreased the power in the alpha and beta bands and oral temperature. The latency to maximum effect varied linearly from 3 hours 40 minutes at 12:00 hours to 1 hour at 21:00 hours. These findings indicate that melatonin possesses a time-dependent hypnotic effect. It is possible that the nocturnal rise in melatonin production initiates a cascade of events leading to activation of somnogenic structures, or perhaps that one of the melatonin metabolites possesses hypnotic effects. This hypothesis is further supported by additional findings, showing diminished levels of endogenous melatonin in elderly insomniacs compared to normal elderly who did not suffer from sleep disorders [REDACTED]. These findings also raise the possibility that precisely timed exogenous melatonin may be beneficial in some forms of insomnia. In the study [REDACTED], there was a correlation between disturbances of rhythm of 6-sulphatoxymelatonin excretion and poor sleep quality in elderly subjects and they concluded that melatonin deficiency seems to be a key variable in the incidence of sleep disorders in elderly people and melatonin replacement therapy may prove beneficial [REDACTED].

In another study, the combined use of slow-release caffeine and melatonin improved several jet lag symptoms during an eastbound flight. For travel of 11 - 13 hours, whether eastbound or westbound, available data from limited field studies indicate that a combination of melatonin, exposure to outdoor light, and exercise have a potent ameliorative effect on jet lag symptoms [REDACTED].

The efficacy of three melatonin formulations for circadian phase advance and delay: (a) 3 mg Regular Release (RR), (b) 3 mg Sustained Release (SR), and (c) 3 mg Surge-Sustained Release (SSR; consisting of 1 mg RR and 2 mg SR) was evaluated [REDACTED]. Circadian phase advances or delays were assessed in two separate experiments using plasma melatonin levels as a parameter. Thirteen normal healthy male subjects aged 26 to 53 years were chosen for experiment 1 (circadian phase advance) and nine normal healthy male subjects aged 26 to 54 years were included in experiment 2 (circadian phase delay). In both studies, a fast-release melatonin preparation induced the expected phase changes. There were no differences in phase advance efficacy among the three melatonin release preparations, while in the phase-delay study, phase shifts for the sustained release preparations could not be determined due to persistent high melatonin levels during sampling times, however, a fast-release melatonin preparation is effective for reducing circadian misalignment for both eastward and westward travel.

In another study, sedentary volunteers (75 subjects crossing 13 time zones on an eastbound flight from Sydney to Buenos Aires, and 49 subjects on a westbound flight from Buenos Aires to Sydney, both by a transpolar route) were selected for investigation [REDACTED]. Passengers on the eastbound flight received 3 mg of melatonin daily 30 minutes before their expected bedtime at Sydney, beginning on the day of the flight and continuing throughout the period of their trip. All subjects were advised to perform their normal routine and to walk outdoors for at least 30 minutes at two restricted times of the day. Passengers on the westbound flight took 3 mg melatonin on the day of their flight to Buenos Aires at the expected sleeping time at Buenos Aires and continued it for 8 days in Buenos Aires. On reaching Buenos Aires, all volunteers were advised to perform their normal routines and to walk outdoors for

2.5 Clinical overview

at least 30 minutes at the same two restricted periods of the day as in Sydney. Subjects were also advised to maintain sleep diaries throughout the period of study. The sleep log diaries included the evaluation of sleep quality, morning freshness, and daily alertness on a visual analogue scale [REDACTED]. The mean resynchronization rate was 2.27 ± 1.1 days during the eastbound flight and 2.54 ± 1.3 days for the westbound flight. These findings compared favourably to the expected minimal resynchronization rate after 13 hours of flight without any treatment, thus supporting the conclusion that jet lag symptoms can be significantly reduced by the carefully timed application of melatonin, light exposure, and physical activity.

In two studies included in the meta-analysis [REDACTED], 10 mg of melatonin maintained sleep duration of 7 – 8 hours at the destination (during a training mission involving rapid deployment to the Middle East and night operations) compared to 5 – 7 hours in placebo group [REDACTED]. In the study [REDACTED], melatonin 5 mg at bedtime for 7 consecutive days after westbound flight produced significant effect on sleepiness [-14.00 (-29.08, 1.08) Mean difference (95 % CI)] in 36 volunteers.

[REDACTED] focused on the effects of air travel sleep deprivation and jet lag disorder. To analyse the results of the study, a phase response curve was generated for all patients. Results indicated that if 3 mg of exogenous melatonin is taken just prior to usual bedtime as a sleep aid, minimal phase advances occur (< 0.5 hours in 3 days) [REDACTED]. They demonstrated that exogenous melatonin can phase delay as well as phase advance the human circadian clock and shows the optimal time to administer the dosage form to achieve a desired phase shift. It also demonstrates that using exogenous melatonin as a sleep aid at night, has minimal phase shifting effects, but that taking it near the end of the sleep episode may inadvertently phase delay the circadian clock [REDACTED].

2.5.4.1.2 Open studies

The process of re-entrainment of circadian melatonin rhythm was investigated in six subjects [REDACTED]. Except during 24- h blood sampling, the subjects were exposed to natural zeitgeber (time giver) outdoors and given 3 mg melatonin at 23:00 h. The subjects were exposed to bright sunlight from 3000 to 12000lx. All of them showed orthodromic re-entrainment without taking melatonin. Melatonin accelerated the rate of the re-entrainment of the circadian melatonin rhythm and was useful to jet travel from Tokyo to Los Angeles. In a later study of the same author, the effect of 3 mg of melatonin on the rate of re-entrainment of plasma melatonin rhythm after an 11-h eastward flight was assessed. Subjects were exposed to natural zeitgeber outdoors and took 3 mg of melatonin at 20:00 h local time on the days when no blood sampling was done. Antidromic re-entrainment was dominant whereby melatonin administration in the evening promoted re-entrainment. Melatonin accelerated the rate of re-entrainment by 15 min per day and alleviated the jet lag symptoms [REDACTED].

2.5.4.1.3 Reviews and Meta-analyses

The [REDACTED] meta-analysis [REDACTED] found that melatonin, taken close to the target bedtime at the destination (10 pm to midnight), decreased jet-lag from flights crossing five or more time zones, by including ten trials that met the inclusion criteria.

The results of meta-analysis are presented below in Figure 8, Figure 9 and Figure 10.

2.5 Clinical overview




Figure 8 Comparison of Melatonin versus placebo – Outcome I for Global Jet Lag ratings: Eastward flights




Figure 9 Comparison of Melatonin versus placebo – Outcome II for Jet Lag ratings: Westward flights




Figure 10 Comparison of Melatonin versus placebo: Eastward flights, proportion of people with jet lag score > 60

2.5 Clinical overview

Table IX Outcomes from [REDACTED] Meta-analysis [REDACTED]. Moderate certainty: good indication of the likely effect

Melatonin for Jet Lag syndrome				
Population	Healthy individuals traveling across more than five time zones			
Intervention	Melatonin			
Comparison	Placebo			
Outcomes	Absolute effect*		Relative effect (95 % CI)	Certainty of the evidence (GRADE)
	Without melatonin	With melatonin		
	Difference: patients per 1000			
Global Jet Lag symptoms (0 to 100 scale)	45 points per 1000	27 points per 1000	MD-17.74 (-23.98 to -11.50)	+++ Moderate
	Difference: 18 points less (Margin error: 12 to 24 points less)			
<i>MD: Mean Difference</i> <i>Margin of error: 95 % Confidence Interval (CI)</i> <i>Grade: Evidence grades of the GRADE Working Group</i>				
<i>*The risk Without melatonin is based on the risk in the control group of the trials. The risk With melatonin (and its margin of error) is calculated from relative effect (and its margin of error).</i>				
<i>†The certainty of the evidence was lowered one level due to the risk of bias because most studies did not adequately describe methods.</i>				

According to this meta-analysis, the daily doses of melatonin between 0.5 and 5 mg are similarly effective, except of people that fall asleep faster and sleep better after 5 mg than 0.5 mg. Doses above 5 mg appear to be no more effective. The relative ineffectiveness of 2 mg slow-release melatonin suggests that a short-lived higher peak concentration of melatonin works better. The benefit is likely to be greater the more time zones are crossed, and less for westward flights. The meta-analysis clearly demonstrates that Melatonin is remarkably effective in preventing or reducing jet lag, and occasional short-term use appears to be safe. It should be recommended to adult travellers flying across five or more time zones, particularly in an easterly direction, and especially if they have experienced jet lag on previous journeys. However, travellers crossing 2 - 4 time zones can also use it if need be. However, it should be noted that individuals differ greatly in the experience of jet-lag, with some travellers extremely affected while others who may have flown the same route may report no jet lag symptoms. This also suggests that individual differences may strongly influence the effectiveness of melatonin.

In the Cochrane review of [REDACTED] it was concluded that melatonin is remarkably effective in preventing or reducing jet lag, and occasional short-term use appears to be safe. In most of the studies evaluated in this review, polysomnography records were evaluated, along with wrist actigraphy, visual analog scales and questionnaires [REDACTED]. The review demonstrated that melatonin decreases the symptoms of jet lag and accelerates the return of normal alertness and energy levels. However, it is recommended to adult travellers flying across five or more time zones, particularly in an easterly direction, and especially if they have experienced jet lag on previous journeys. Travellers crossing 2 - 4 time zones can also use it if need be [REDACTED].

[REDACTED] randomized trials in order to evaluate the efficacy of melatonin in jet lag disorder. The authors followed the GRADE approach and concluded that the use of oral melatonin reduces the symptoms associated with jet lag syndrome [REDACTED]. This review did not conclude regarding the association of melatonin to adverse effects (nausea, tiredness, drowsiness and headaches), however no serious adverse effects were recorded in any of the clinical trials included in this review.

2.5 Clinical overview

The efficacy of exogenous Melatonin in managing secondary sleep disorders (jet lag and shift work) has been reviewed [REDACTED]. Sleep onset latency was the primary outcome in this meta-analysis. Pooled analysis of 7 studies (n = 154) demonstrate that exogenous administration of melatonin lowers Sleep Onset Latency (SOL) (Total mean difference: -2.48 min, 95 % CI: -4.56, -0.40) versus placebo (Figure 11)




Figure 11 Effects of melatonin on SOL. This forest plot demonstrates that exogenous administration of melatonin lowers sleep onset latency [REDACTED].

Total sleep time was the secondary outcome in this meta-analysis and finally 3 studies reported the efficacy of melatonin in total sleep time. Exogenous administration of melatonin increased total sleep time (Total mean difference: 29.27 min, 95 % CI: 6.68, 51.86) (Figure 12)




Figure 12 Effects of melatonin on TST. This forest plot suggests that exogenous administration of melatonin increases total sleep time [202].

Sleep efficiency was also the secondary outcome in this meta-analysis and 3 studies reported the efficacy of melatonin in sleep efficiency (SE). Analysis of the 3 studies (N=71) suggested that exogenous melatonin has no meaningful actions on sleep efficiency (Total mean difference: 1.46, 95 % CI: -0.43, 3.35) (Figure 13).




Figure 13 Effects of melatonin on SE [REDACTED].

2.5 Clinical overview

The results of the meta-analysis demonstrated that exogenous melatonin lowers sleep onset latency and increases total sleep time, whereas it has little if any effect on sleep efficiency. The study [REDACTED] clearly supports the use of melatonin as a management for patients with secondary sleep disorders [REDACTED].

2.5.4.2 SHIFT WORK DISORDER (SWD)

Several studies have been conducted with workers who undertake shift work (including night shifts) in their present jobs and who may or may not have sleep problems.

The negative effects of shift work on alertness and sleeping can be classified as either work-directed, such as changes in the shift system, or worker-directed, such as pharmacological or non-pharmacological interventions [REDACTED]. Pharmacological interventions may help shift workers by either by reducing sleepiness and improving alertness during work-shifts, or by reducing sleep disturbances while off work. In this case, there are two categories of drugs, i.e. substances to help shift workers prevent drowsiness or improve alertness during shift work, or substances to improve sleep quality or sleep length after a shift work period.

The following sections present the efficacy of Melatonin in shift work disorder by reducing the sleepiness and improving alertness in people who undertake shift works.

2.5.4.2.1 Comparative Studies

The efficacy of 3 mg melatonin taken 30 min before night time sleep on shift-workers with difficulty falling asleep was recently evaluated [REDACTED]. Severity Index (ISI) were applied to find out shift workers with difficulty falling asleep. A randomized, double-blind, placebo-controlled crossover study with periods of 3 night and washouts of 2 weeks comparing melatonin with placebo was performed. Night time sleep parameters obtained from somnowatch including total sleep time (TST), sleep onset latency (SOL), sleep efficiency (SE) and waking after sleep onset (WASO) were analyzed. Among 295 workers, 103 had difficulty falling asleep. Finally, from 50 randomly selected workers with difficulty falling asleep, 39 workers completed the study. Melatonin treatment significantly increased SE and decreased SOL in comparison with baseline and taking placebo. The study showed that melatonin treatment significantly increased sleep efficiency and decreased sleep onset latency in comparison with baseline and taking placebo. Sleep efficiency was increased from 82.1 % at baseline to 85.5 % after melatonin therapy and sleep onset latency was decreased from 0.27 h at baseline to 0.20 h after melatonin therapy [REDACTED].

The effects of melatonin and bright light on adaption to night work were evaluated [REDACTED]. This was the first study (a randomized placebo-controlled crossover study) comparing the effects of melatonin (3 mg of melatonin, 1 hour before bedtime), with respect to subjective and objective measures of sleepiness and sleep in relation to night work among real shift workers. Melatonin gave a significant reduction in sleepiness, when compared with the placebo. This reduction in sleepiness was present during the day shift, but not during the night shift. Melatonin gave significant lower values for irresistible sleepiness and fighting sleep when compared with the placebo during the day shift. Additionally melatonin gave significantly longer total sleep time than the placebo and sleep efficiency was significantly higher after the intake of melatonin when compared with after exposure to bright light, whereas there were no significant differences between the placebo and the bright light. The participants also scored low on anxiety and depression, according to the rating scale. Melatonin increased the sleep onset latency when compared with the effect of bright light and the placebo during

2.5 Clinical overview

night shift. The authors concluded that the effects of melatonin are depended on the dose and time of administration [REDACTED].

In the study [REDACTED], Melatonin treatment (3 mg) improved attention, evidenced by fewer omission errors, but had no significant effect on measures of sleep or mood, particularly fatigue. A beneficial effect of melatonin in attention may occur independently of improved sleep or decreased fatigue [REDACTED]. However, melatonin did not improve sleep duration, vigour or fatigue. The authors explained the variability in responses and the inconsistency of results among other studies, due to pharmacogenetic characteristics, individual tolerance to shift work and a relationship of response to melatonin with individual tolerance to shift work, however in all cases, administered melatonin for 2 weeks was well tolerated.

Compared to placebo, and to no treatment, melatonin (5 mg) taken at the desired bedtime improved problems related to sleep and increased alertness during working hours, especially during the early morning. Melatonin resulted in an increase in rated sleep quality and in its duration relative to both baseline and placebo conditions. The increased sleep duration with melatonin resulted in a somewhat delayed sleep offset, but there was no evidence that melatonin affected either sleep onset times or sleep latency. Melatonin improved also sleep quality compared to baseline and placebo during the seven night sleeps following the night shift period, but without significant effects on onset, offset or duration [REDACTED].

In another double blinded, randomized crossover study the authors examined whether melatonin is effective in helping emergency medical services personnel who work rotating night shifts, reset their biological clock and minimize circadian rhythm disruption [REDACTED]. Melatonin was associated with significantly fewer interim awakenings during day sleep when compared with placebo. However, this benefit was not associated with any significant effects on sleep latency, duration, or efficiency. Although these scores represent a 12 % improvement in sleep quality from melatonin, this difference was not statistically significant and did not produce concomitant improvements in night shift performance. The rapid metabolism of melatonin is probably responsible for the inability to detect a significant improvement in overall sleep duration or sleep efficiency. It was concluded that high-dose (80 to 240 mg orally) or repeated low-dose administration are required, in order to maintain effective serum concentrations of melatonin throughout daytime sleep.

In another randomized, double-blind, placebo-controlled crossover trial, it was investigated whether melatonin taken prior to attempted daytime sleep sessions will improve daytime sleep quality, night-time sleepiness, and mood state in Emergency Medicine (EM) Residents, changing from daytime to night-time work schedules [REDACTED]. Among the 19 volunteers studied, there was no difference in sleep efficiency (91.16 % vs 90.98 %, NS), sleep duration (379.6 min vs 342.7 min, NS), or sleep latency (7.59 min vs 6.80 min, NS), between melatonin and placebo, respectively. In addition, neither the POMS (Profile of Mood States) total mood disturbance (5.769 baseline vs 12.212 melatonin vs 5.585 placebo, NS) nor the SSS (1.8846 baseline vs 2.2571 melatonin vs 2.1282 placebo, NS) demonstrated a statistical difference in night-time mood and sleepiness between melatonin and placebo, when 1 mg of melatonin was administered. The small sample size magnifies the detrimental effects of non-compliance with either medication dosing or mood and sleep testing.

The effect of oral intake of 5 mg melatonin taken 30 minutes before night time sleep, on insomnia parameters (associated with night work-shift-work nurses with insomnia) as well as subjective sleep onset latency, number of awakenings and durations of sleep was examined also in a double-blind, randomized, placebo-controlled crossover study with 118 participants. There was evidence of an effect

2.5 Clinical overview

of melatonin treatment on Sleep Onset Latency (SOL). Specifically, the mean SOL for subjects being treated with melatonin was significantly lower than the mean SOL for subjects given placebo. Furthermore, means for both the subjects given melatonin and those given placebo were significantly different from the baseline mean [REDACTED].

The effects of administration of exogenous melatonin (10 mg sublingual melatonin) in 18 subjects, in a double-blind, placebo-controlled crossover trial were determined [REDACTED]. Melatonin was administered each morning during one string of nights and the other substance during another string of nights of equal duration. As measured on the basis of SSS (Stanford Sleepiness Scale), melatonin improved alertness at the end of a night shift over placebo (median difference, .5; 95 % CI, .04 to 1.0). They noted no difference between melatonin and placebo in alertness at the beginning of a night shift (median, 0; 95 % CI, -.4 to .9) or at the midpoint of a night shift (median, 0; 95 % CI, -.4 to .5). When the melatonin and placebo periods were combined, median SSS scores increased as the night shifts progressed from 2 just before a shift to 2.25 at the midpoint, to 4.75 just after a night shift.

The beneficial effects from exogenous melatonin in emergency physicians after intermittent night-shift duty were determined [REDACTED]. 5 mg of melatonin or placebo were administered to subjects and in the global assessment of recovery there was no difference between melatonin and placebo (60.4 ± 16.9 and 58.9 ± 14.5 , respectively). There were no differences in sleep quality, duration or tiredness scores, sleep latency, hours of sleep obtained per night, and night or early awakening at any measurement point. Additionally, Profile of Mood States and neuropsychologic test performances were similar. On the other hand, Yoon et al administered melatonin or placebo on the second and third days of each treatment (6 mg melatonin) to twelve nightshift nurses. The SPTs (Sleep Period Time) and TSTs (Total Sleep Time) were significantly improved by melatonin administration. However, the improvement in nocturnal alertness was only marginal and attenuation of morning sunlight exposure had no effect on the findings [REDACTED]. This study indicates that the beneficial effects of melatonin treatment are not increased by attenuation of morning sunlight exposure. This means that the masking sleep-promoting effect of melatonin is more influential than its phase-shifting effect in improving nightshift adaptation. This explanation is supported by the lack of melatonin benefit on the 4th day, when the phase-shifting effect of melatonin is expected to be distinguishable from its masking effect.

[REDACTED] tested whether melatonin can facilitate phase shifts in a simulated night-work protocol. Subjects (n = 32) slept in the afternoons/evenings before night work (a 7-hour advance of the sleep schedule). They took melatonin (0.5 mg or 3.0 mg) or placebo before the first four of eight afternoon/evening sleep episodes at a time when melatonin has been shown to phase advance the circadian clock. Melatonin produced larger phase advances than placebo in the circadian rhythms of melatonin and temperature. Average phase advances (\pm SD) of the dim light melatonin onset were 1.7 ± 1.2 h (placebo), 3.0 ± 1.1 h (0.5 mg), and 3.9 ± 0.5 h (3.0 mg). A measure of circadian adaptation, shifting the temperature minimum enough to occur within afternoon/evening sleep, showed that only subjects given melatonin achieved this goal (73 % with 3.0 mg, 56 % with 0.5 mg, and 0 % with placebo) [REDACTED]. There is probably an upper limit to the size of phase shift that can be induced in 1 day; dose-dependent curves for phase shifting with light exhibit a plateau (35), and in studies with large abrupt advances of sleep/dark, the maximum phase advances achieved were never more than 2 h/d [REDACTED]. The second study [REDACTED] utilized a placebo-controlled, double-blind, cross-over design. Subjects participated in two 6-day laboratory sessions. Each session included one adaptation night, two baseline nights, two consecutive 8-hour night shifts followed by 8-hour daytime sleep

2.5 Clinical overview

episodes and one recovery night. Subjects took 1.8 mg sustained-release melatonin 0.5 hour before the two daytime sleep episodes during one session, and placebo before the daytime sleep episodes during the other session. Sleep was recorded using polysomnography. Sleepiness, performance, and mood during the night shifts were evaluated using the Multiple Sleep Latency Test (MSLT) and a computerized neurobehavioral testing battery. Melatonin prevented the decrease in sleep time during daytime sleep relative to baseline, but only on the first day of melatonin administration. Melatonin increased also sleep time more in subjects who demonstrated difficulty in sleeping during the day. Melatonin had no effect on alertness on the MSLT, or performance and mood during the night shift. There were no hangover effects from melatonin administration. These findings suggest that although melatonin can help night workers obtain more sleep during the day, they are still likely to face difficulties working at night because of circadian rhythm misalignment.

In the latest randomized clinical trial [REDACTED], 3 mg of Melatonin were administered to emergency medicine residents who undertake shift work [REDACTED]. The study consisted of four phases within a month with intervention periods of two nights and washouts of six days. Shift workers had nine-hour shifts on 6 consecutive days. 3 mg of Melatonin or placebo were administered at the end of shift's cycle for 2 consecutive nights. Daytime sleepiness was calculated by KSS and mood status by POMS. The authors observed that in the melatonin group, night awakening on the first night was less than the placebo group ($p=0.020$), daytime drowsiness decreased by taking the second dose of melatonin ($p=0.021$) (calculated by KSS score) and melatonin could significantly reduce this rate on the second night ($p=0.003$) within its group [REDACTED].

2.5.4.2.2 Reviews and Meta-analyses

[REDACTED] performed recently a meta-analysis to evaluate the effects of pharmacological interventions to reduce sleepiness or to improve alertness at work and decrease sleep disturbances whilst off work, or both, in workers undertaking shift work in their present job and to assess their cost-effectiveness (Table X). Sleep time (next day and next night [Outcomes 1 & 2]), sleep onset latency (next day and next night [Outcomes 3 & 4]), sleep quality (assessed by Visual Analog Scale), alertness during the night shift work (assessed by Visual Analog Scale) and sleepiness during the night shift work (assessed by KSS-Karolinska Sleepiness Scale) were assessed (Figure 14, Figure 15, Figure 16).

2.5 Clinical overview

Table X Effect of Melatonin o Shift Work Disorder

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
Total sleep time, next day	7	263	Mean Difference (IV, Fixed, 95 % CI)	24.34 [9.82, 38.86]
Diary-based sleep time	6	225	Mean Difference (IV, Fixed, 95 % CI)	23.49 [8.49, 38.49]
Actigraphy based sleep time	1	38	Mean Difference (IV, Fixed, 95 % CI)	37.0 [-20.87, 94.87]
Total sleep time, next night	3	234	Mean Difference (IV, Fixed, 95 % CI)	16.97 [3.71, 30.22]
Diary-based sleep time	2	202	Mean Difference (IV, Fixed, 95 % CI)	19.05 [4.47, 33.63]
Actigraphy-based sleep time	1	32	Mean Difference (IV, Fixed, 95 % CI)	7.0 [-24.88, 38.88]
Sleep onset latency, next day	5	148	Mean Difference (IV, Random, 95 % CI)	0.15 [-2.18, 2.48]
Diary-based sleep onset latency	4	118	Mean Difference (IV, Random, 95 % CI)	0.80 [-1.15, 2.75]
Actigraphy-based sleep onset latency	1	30	Mean Difference (IV, Random, 95 % CI)	-9.0 [-18.60, 0.60]
Sleep onset latency, next night	3	-	Mean Difference (IV, Random, 95 % CI)	Totals not selected
Diary-based sleep onset latency, next night	2	-	Mean Difference (IV, Random, 95 % CI)	0.0 [0.0, 0.0]
Actigraphy-based sleep onset latency, next night	1	-	Mean Difference (IV, Random, 95 % CI)	0.0 [0.0, 0.0]
Sleep quality (visual analog scale)	4	291	Std. Mean Difference (IV, Fixed, 95 % CI)	0.08 [-0.15, 0.31]
Alertness during the night shift work (VAS)	1	-	Mean Difference (IV, Fixed, 95 % CI)	Totals not selected
Sleepiness during the night shift work (KSS)	1	-	Mean Difference (IV, Fixed, 95 % CI)	Totals not selected
Sleepiness during the day shift work (KSS)	1	-	Mean Difference (IV, Fixed, 95 % CI)	Totals not selected

2.5 Clinical overview




Figure 14 Melatonin versus placebo (Outcome I) ██████████ for sleepiness and sleep disturbances caused by shift work (next day)




Figure 15 Melatonin versus placebo (Outcome II) ██████████ for sleepiness and sleep disturbances caused by shift work (next night)

2.5 Clinical overview




Figure 16 Melatonin versus placebo, Outcome III. Sleep onset latency, next day

The results showed that melatonin (1 to 10 mg) after the night shift may increase sleep length during daytime sleep (mean difference (MD) 24 minutes, 95 % confidence interval (CI) 9.8 to 38.9; seven trials, 263 participants) and night-time sleep (MD 17 minutes, 95 % CI 3.71 to 30.22; three trials, 234 participants) compared to placebo. Outcome measures in the studies included in this meta-analysis were KSS (Karolinska Sleepiness Scale), MSLT (Multiple Sleep Latency Test) and psychomotor tasks. The authors did not find a dose-response effect.

As described also in Section 2.5.4.1.3 of the clinical overview, the recent meta-analysis demonstrated that exogenous melatonin lowers sleep onset latency and increases total sleep time, whereas it has little if any effect on sleep efficiency. This study clearly supports the use of melatonin as a management for patients with secondary sleep disorders.

2.5.4.2.3 Open studies

There is only one open study available in the public domain. A total of 1533 nurses participated in a survey on shift work, sleep and health responded to questionnaires at baseline and about two years later at follow-up. The results of the study showed a significant reduction in the prevalence of SWD from baseline to follow-up, from 35.7 % to 28.6 %. Significant risks of having SWD at follow-up and the following variables measured at baseline; number of nights worked the last year (OR = 1.01, 95 % CI = 1.01 - 1.02), having SWD (OR = 5.19, 95 % CI = 3.74 - 7.20), composite score on the Epworth Sleepiness Scale (OR = 1.08, 95 % CI = 1.04 - 1.13), use of melatonin (OR = 4.20, 95 % CI = 1.33 - 13.33), use of bright light therapy (OR = 3.10, 95 % CI 1.14 - 8.39), and symptoms of depression measured by the Hospital Anxiety and Depression Scale (OR = 1.07, 95 % CI = 1.00 - 1.14). Additionally, leaving night work between baseline and follow-up was associated with a significant reduced risk of SWD at follow-up (OR = 0.12, 95 % CI = 0.07 - 0.22).

2.5.4.3 OTHER USES

The actions of melatonin on the sleep-wake cycle in different disorders have been investigated and described below, in Sections 2.5.4.3.1, 2.5.4.3.2, 2.5.4.3.3, 2.5.4.3.4 and 2.5.4.3.5.

2.5 Clinical overview

2.5.4.3.1 Advanced Sleep–Wake Phase Disorder (ASWPD)

Advanced Sleep Phase Disorder (ASWPD) is characterized by a stable sleep schedule that is several hours earlier than the conventional or desired time [REDACTED]. The mechanisms leading to this condition are unknown, but hypotheses have usually been the opposite of those thought to underlie DSWPD. There are no systematic reports of melatonin administration for ASWPD, but consideration of the melatonin PRC provides a rationale for low-dose administration after early morning awakenings and upon final arising in the morning [REDACTED].

2.5.4.3.2 Delayed Sleep–Wake Phase Disorder (DSWPD)

Delayed Sleep–Wake Phase Disorder (DSWPD) is a circadian rhythm sleep disorder characterized by abnormally late sleep and wake time [REDACTED]. It occurs mainly in young individuals and accounts for 10 % of chronic sleep disorders. The disorder is often misdiagnosed as sleep-onset insomnia [REDACTED].

The most common treatment approaches for DSWPD are based on the administration of bright light and/or exogenous melatonin with or without adjunct behavioural instructions. [REDACTED] investigated the short- and long-term effects on sleep of a DSWPD treatment protocol involving administration of timed bright light and melatonin alongside gradual advancement of rise time in adolescents and young adults with DSWPD in a randomized controlled trial and an open label follow-up study [REDACTED]. The participants were randomized to receive treatment for two weeks in one of four treatment conditions: dim light and placebo capsules, bright light and placebo capsules, dim light and melatonin capsules or bright light and melatonin capsules. In a follow-up study, participants were re-randomized to either receive treatment with the combination of bright light and melatonin or no treatment in an open label trial for approximately three months. Light and capsules were administered alongside gradual advancement of rise times. The main end points were sleep as assessed by sleep diaries and actigraphy recordings and circadian phase as assessed by salivary Dim Light Melatonin Onset (DLMO). During the two-week intervention, the timing of sleep and DLMO was advanced in all treatment conditions as seen by about 1 hour advance of bed time, 2 hours advance of rise time and 2 hours advance of DLMO in all four groups. Sleep duration was reduced with approximately 1 hour. At three-month follow-up, only the treatment group had maintained an advanced sleep phase. Sleep duration had returned to baseline levels in both groups. In conclusion, gradual advancement of rise time produced a phase advance during the two-week intervention, irrespective of treatment condition. Termination of treatment caused relapse into delayed sleep times, whereas long-term treatment with bright light and melatonin (three months) allowed maintenance of the advanced sleep phase.

The actions of melatonin on the sleep–wake cycle were investigated by means of a randomised, double-blind, placebo-controlled trial in 8 subjects with a delayed sleep phase syndrome attending a sleep disorders clinic [REDACTED]. Drug or placebo was given at 2200 hour, 5 hours before the mean time of sleep onset determined by pre-trial sleep logs. In all 8 subjects sleep onset time [mean advance 82 (range 19 – 124) min; $p < 0.01$] and wake time [117 (10 – 187) min; $p < 0.01$] were significantly earlier during melatonin treatment than during placebo. Mean total sleep time was slightly less on melatonin (8 h & 12 min) than on placebo (8 h & 46 min). Alertness acrophase calculated from the subjects' ratings of alertness made every 2 h while awake was unaltered. Melatonin may act as a phase-setter for sleep–wake cycles in subjects with a delayed sleep phase syndrome.

The influence of 5 mg of melatonin on vigilance and cognitive processing speed in DSWPD patients was investigated [REDACTED] in a randomized controlled-placebo trial. Melatonin was administered 5 hours before the endogenous melatonin starts to rise in dim light (DLMO) and

2.5 Clinical overview

improved vigilance and cognitive processing speed in DSWPD patients. These observed effects might not completely within 10 days after stopping melatonin treatment.

██████████ compared health-related quality of life of DSWPD patients with a random Dutch sample and four samples of patients with other chronic conditions ██████████. The effectiveness of treatment with 5 mg of melatonin on the quality of life of DSWPD patients was also investigated. MOS SF-36 scales scores (Medical Outcome Study Short Form -36) were significantly lower in DSWPD patients relative to age- and gender- adjusted norms for the Dutch sample. Melatonin treatment improved all scales, except the scale "role due to emotional problems".

In the randomized, double-blind, placebo-controlled crossover trial ██████████, the effects of exogenous melatonin (5 mg daily for 4 weeks) on sleep, daytime sleepiness, fatigue, and alertness were investigated in 22 patients with delayed sleep phase syndrome whose nocturnal sleep was restricted to the interval from 24:00 to 08:00 hours. In the 20 patients who completed the study, sleep onset latency was significantly reduced while subjects were taking melatonin as compared with both placebo and baseline. There was no evidence that melatonin altered total sleep time (as compared with baseline total sleep time), but there was a significant decrease in total sleep time while patients were taking placebo. Melatonin did not result in altered scores on subjective measures of sleepiness, fatigue, and alertness, which were administered at different times of the day. After an imposed conventional sleep period (from 24:00 to 08:00), subjects taking melatonin reported being less sleepy and fatigued than they did while taking placebo ██████████.

The effectiveness of melatonin to advance the timing of sleep and circadian phase in individuals with DSWPD was tested ██████████. Two doses of melatonin were tested: 0.3 mg and 3 mg and the administration of melatonin was double-blinded. Both doses of melatonin advanced the circadian phase of endogenous melatonin. The magnitude of phase advance in dim-light melatonin onset correlated strongly with the time of melatonin administration, with earlier times being more effective ($r^2 = 0.94$, $P < 0.0001$). Administration of placebo had no effect on the timing of DLMO, whereas melatonin (0.3 and 3.0 mg) advanced DLMO and T_{min} . For the melatonin treatment group as a whole, 4 weeks of melatonin administration induced robust advances in DLMO and T_{min} . With this small sample size, no evidence of a difference in the ability of the 2 doses, 0.3 and 3.0 mg of melatonin, to phase advance DLMO when administered over the course of 4 weeks was obtained and this is consistent with the finding that low doses of melatonin can effectively entrain circadian rhythms in the blind ██████████. On average, subjects fell asleep 27 minutes earlier and woke up 47 minutes earlier than before treatment. The 47-minute advance in sleep offset, though not reaching statistical significance, could be clinically relevant for patients with difficulty in meeting work and school schedules. Similar, though weaker, relationships were obtained between the timing of melatonin administration and changes in sleep time.

A meta-analysis of data of randomized controlled trials involving individuals with Delayed Sleep-Wake Phase Disorder that were published, compared melatonin with placebo, and reported one or more of the following: endogenous melatonin onset, clock hour of sleep onset, wake-up time, sleep-onset latency, and total sleep time. The 5 trials including 91 adults and 4 trials including 226 children showed that melatonin treatment advanced mean endogenous melatonin onset by 1.18 hours [95 % confidence interval (CI): 0.89 - 1.48 h] and clock hour of sleep onset by 0.67 hours (95 % CI: 0.45 - 0.89 h). Melatonin decreased sleep-onset latency by 23.27 minutes (95 % CI: 4.83 - 41.72 min). The wake-up time and total sleep time did not change significantly ██████████.

2.5 Clinical overview

██████████ administered 5 mg of melatonin, based on the favourable results of Jan and Donell ██████████ who treated successfully more than 100 mentally handicapped children with 2.5 mg to 10 mg melatonin. This dose is much higher than the 0.3 mg ██████████ used in the treatment of 13 children with Angelman's syndrome. ██████████ showed that melatonin maximally advances circadian rhythms when administered 5 hours before melatonin onset. Five hours before melatonin onset should have meant that several children should have to take the melatonin at 4 PM. In a pilot study, we found that most children who received melatonin at that time became intolerably sleepy within 30 to 60 minutes after melatonin intake 2003 ██████████.

2.5.4.3.3 Non-24-h Sleep-Wake Rhythm Disorder (N24SWD) or Free-Running Disorder (FRD)

Normal (unaffected) subjects who are maintained in an inpatient research environment devoid of time cues eventually develop free-running rhythms ██████████. The earliest studies of human subjects in time-free environments concluded that most people have an intrinsic circadian period much longer than 24 hours, averaging about 24.5 hours; however, more recent studies using the forced de-synchrony protocol have found the average to be significantly shorter; i.e., 24.15 hours ██████████. In either case, the human circadian period is usually longer than 24 hours. Patients with free-running rhythms have circadian cycles that mimic those of subjects in time-free environments, and thus are thought to reflect a failure of entrainment. The condition is very rare in normally sighted people, but quite common in the totally blind who have no access to the entraining effects of the light/dark cycle ██████████.

Because the condition is rare in sighted people, the data consist almost entirely of level 4, single case reports, ██████████ or studies with few subjects, ██████████ ██████████ recently reported an accumulated series of 57 patients. A high proportion (about 25 %) of sighted people with FRD have associated psychiatric disorders ██████████. A similar proportion of patients have a prodromal history of DSWPD ██████████.

Four level 4 case reports of successful treatment of sighted FRD with melatonin administered around the hour of the desired bedtime, when it would be predicted to cause a phase advance, are available ██████████. The most common dose was 3 mg and the duration of treatment ranged from one month to six years. In one study, ██████████ the treatment was interrupted for a double-blind, placebo-controlled dose escalation.

Following the demonstration of entrainment in animals with free-running rhythms ██████████, melatonin has been tested as a treatment in totally blind people. In addition to several positive case reports (level 4) ██████████, there have been two small single-blind, placebo-controlled melatonin treatment trials demonstrating successful entrainment of free-running rhythms in totally blind people (level 2). In one study ██████████, 3 of 7 subjects entrained to 5 mg of melatonin given for 35 - 71 days at 21:00. In the other study ██████████, 6 of 7 subjects entrained to 10 mg given at the usual bedtime for 3 to 9 weeks. In this study, three of the subjects were given a 10 mg dose that was gradually stepped-down every other week to 0.5 mg. Melatonin treatment on this step-down dosing schedule maintained entrainment, and free-running rhythms recurred after the cessation of treatment. Subsequently, these same subjects were successfully entrained with 0.5 mg de novo (level 4) ██████████. The subject who failed to entrain in the initial trial to 10 mg was subsequently entrained with a 0.5 mg dose (level 4). The effectiveness of the lower dose was attributed to its selective activity on the advance zone of the melatonin phase response curve with no "spillover" to the delay zone. In another recent trial, the 0.5 mg dose entrained 6 of 10 subjects (level 2). In summary, the evidence is compelling that melatonin can entrain the majority of totally blind patients with FRD. Furthermore, a physiological dose (0.5 mg)

2.5 Clinical overview

appears to be as effective as a pharmacological dose (5 mg to 10 mg), and in some cases, more effective.

2.5.4.3.4 Irregular Sleep-Wake Rhythm (ISWR)

ISWR is characterized by the relative absence of a circadian pattern to the sleep-wake cycle. Total sleep time may be comparatively normal, but instead of being consolidated into distinct bout or bouts, sleep times are shortened, and in extreme cases, almost randomly distributed throughout the day and night [REDACTED].

Melatonin has typically been used in studies seeking to improve sleep quality by increasing amplitude rather than phase shift sleep/wake rhythms.

[REDACTED] [REDACTED] [REDACTED] reported some success in treating sleep disturbances in children with presumed ISWR and severe psychomotor retardation. However, this study was a poorly controlled and employed a small sample size. [REDACTED] [REDACTED] reported an incomplete, but nevertheless significant benefit in an open label trial of melatonin (2 to 20 mg) given at bedtime to neurologically multiply-disabled children with chronic sleep wake cycle disorders. A later report [REDACTED] compared Controlled Release melatonin (CR) to Immediate Release (IR) (2 to 12 mg) in a similar population; the CR formulation was found to be superior to IR for sleep maintenance. A trial of melatonin which sought to improve sleep timing and quality in girls with Rett syndrome and associated mental retardation, was negative [REDACTED] [REDACTED].

[REDACTED] [REDACTED] randomized forty-four participants with DSM-IV diagnosis of dementia (Diagnostic and Statistical Manual of Mental Disorders) and comorbid sleep disturbance to a seven-week double blind crossover trial of two weeks of slow release melatonin (6 mg) versus placebo. It should be noted that only 25 out of 44 patients completed the trial. Melatonin had no effect on actigraphically measured total time asleep, number of awakenings, or sleep efficiency. [REDACTED]

[REDACTED] [REDACTED], in a large multi-centre trial, randomized [REDACTED] Alzheimer dementia patients with insomnia and daytime sleepiness to melatonin, 2.5 mg sustained-release; melatonin, 10 mg immediate-release, or placebo. The protocol consisted of 2 to 3 weeks of baseline measurement, 8 weeks of treatment, and 2 weeks placebo washout. Actigraphically monitored sleep was not significantly improved with either melatonin dose or placebo.

2.5.4.3.5 Sleep onset insomnia in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

In the open label study, the effect of a 3 mg dose of melatonin given in the evening, on insomnia, was investigated in 24 children with ADHD [REDACTED]. Immediately after the start of melatonin treatment the subjects fell asleep significantly earlier than before, varying between 15 min to 240 min, with a median value of 135 min in the first week of treatment. The long-term effect, after 3 months, was comparable with the immediate effect after 1 week. Also, a paired student t-test for the time of falling asleep before and after medication was significant ($t = 16.05$, $P < 0.01$). The time of falling asleep after melatonin had been given varied between 15 – 64 minutes. Immediate relapse of insomnia was reported twice when treatment with melatonin had been forgotten during the study period and twice after ending the study. Restarted use of melatonin restored the positive effect. Comparing the long-term effect to the immediate effect showed that melatonin remained effective for at least 3 months. No statistical difference could be shown in the short-term effect of melatonin between those patients who stopped recording data and those who did not ($P < 0.50$). The data indicate that melatonin has a

2.5 Clinical overview

significant effect on the time of falling asleep. Although the study design, a placebo effect and the change of sleeping ritual could have influenced the results, the highly significant difference strongly suggests a positive melatonin effect.

In the study [REDACTED], the effect of melatonin treatment on sleep, behaviour, cognition and quality of life in children with ADHD and chronic onset insomnia was investigated [REDACTED]. Sleep onset advanced by 26.9 ± 47.8 minutes with melatonin and delayed by 10.5 ± 37.4 minutes with placebo ($p < 0.0001$). There was an advance in dim light melatonin onset of 44.4 ± 67.9 minutes in melatonin and a delay of 12.8 ± 60.0 minutes in placebo ($p < 0.0001$). Total time asleep increased with melatonin (19.8 ± 61.9 minutes) as compared to placebo (13.6 ± 50.6 minutes; $p = 0.01$). There was no significant effect on behaviour, cognition, and quality of life, and significant adverse events did not occur.

In a randomized double-blind, placebo-controlled study melatonin was evaluated for its efficacy on sleep hygiene ($n = 27$) in children with ADHD. Melatonin was found clinically and statistically significantly superior to placebo on actigraph measurement of Sleep Onset Latency in children [(SOL), $t(18) = -4.54$, $p < 0.01$] in another trial [REDACTED]. Two-sample t tests of the period and crossover differences indicated a significant difference between the sleep latencies for the two treatments, $t(20) = -3.06$, $p < 0.01$ and a significant period effect, $t(20) = -2.20$, $p < 0.05$, respectively. The effect size of the difference between melatonin and placebo treatment was 0.6. Mean Somnolog SOL on placebo was 62.1 minutes (SD = 26.6) versus mean SOL on melatonin of 46.4 minutes (SD = 26.4). Two-sample t tests of the period and crossover differences indicated a significant difference between the sleep latencies for the two treatments, $t(20) = -3.06$, $p < 0.01$ and a significant period effect, $t(20) = -2.20$, $p < 0.05$, respectively. SOL at the end of open label was 31 minutes ($n = 17$), which was not statistically significantly different from SOL during the randomized melatonin treatment. Sleep duration, however, continued to improve by 23 minutes [$t(12) = 3.90$, $p < 0.01$]. The effect size of the combined sleep hygiene and melatonin intervention from baseline to 90 days' post-trial was 1.7, with a mean decrease in initial insomnia of 60 minutes. Adverse events were generally mild and not different from those recorded with placebo treatment.

Melatonin was used in the study [REDACTED] for the delayed sleep phase syndrome which is associated with ADHD in children. 5 mg of melatonin was administered to 27 children with sleep disorders. The total score of the RAND-GHRI (RAND General Health Rating Index) and FS-II (Functional Status) improved significantly more during melatonin treatment compared to placebo. The magnitude of change was much higher in the melatonin group than in the placebo group, with standardized response means for the RAND-GHRI of 0.69 versus 0.07 and for the FS-II of 1.61 versus 0.64. Melatonin treatment also significantly advanced sleep onset by 57 minutes, sleep offset by 9 minutes, and melatonin onset by 82 minutes, and decreased sleep latency by 17 minutes.

2.5.4.3.6 Effect of exogenous melatonin on sleep onset latency, sleep efficiency and total sleep duration

The effects of exogenous melatonin on sleep onset latency, sleep efficiency and sleep duration were evaluated [REDACTED]. The results of the meta-analysis are presented in Figure 17.

2.5 Clinical overview




Figure 17 (A) Effects of exogenous melatonin on sleep latency. (B) Effects of exogenous melatonin on sleep efficiency. (C) Effects of exogenous melatonin on total sleep duration. Intervals are 95 % confidence intervals for the mean effect [REDACTED].

This meta-analysis supports the hypotheses that melatonin decreases sleep onset latency, increases sleep efficiency, and increases total sleep duration. In spite of the heterogeneity of the data, the present meta-analysis does lend statistical support to the notion that melatonin preparations can improve sleep quality with regard to sleep onset latency, sleep efficiency, and sleep duration.

2.5.4.4 OTHER STUDIES

The effects of exogenous melatonin on nocturnal sleep quantity in critically ill patients were evaluated [REDACTED] in a randomized double-blind placebo-controlled trial with 24 subjects who had undergone a tracheostomy to aid weaning from mechanical ventilation [REDACTED]. Melatonin 10 mg, formulated in an oral liquid and administered for four consecutive nights. Nocturnal sleep time was found 2.5 hours in the placebo group and was found 1 hour longer in the melatonin group, corresponding to an increase of 47 %, although the difference did not reach statistical significance. They obtained also a statistically significant reduction of 7 % in BIS (Bispectral Index) AUC with melatonin administration, suggesting sleep improvement.

In the double-blind placebo-controlled randomized pilot study [REDACTED], oral melatonin (3 mg) was administered to tracheostomised patients with nocturnal sleep. Although melatonin was well absorbed and this standard dose increased blood levels approximately 1000-fold, these high levels failed to increase observed nocturnal sleep or induce other observable benefits in tracheostomised ICU (Intensive Care Unit) patients [REDACTED]. In another study healthy volunteers were exposed to artificial insomnia participated in a double-blind, placebo controlled, parallel group design study. Melatonin

2.5 Clinical overview

administered as a single oral pharmacological dose of 80 mg at bedtime has the properties of a real hypnotic substance. It affected sleep initiation and sleep maintenance by reducing the time awake before sleep onset, the sleep latency, and the number of awakenings during the total sleep period; in addition, it improved sleep efficiency. Moreover, sleep architecture was altered as sleep stage 1 decreased and sleep stage 2 increased, modifications repeatedly reported as typical for anxiolytic sedatives [REDACTED].

[REDACTED] examined how photic and non-photic time cues may be combined by the human circadian system by assessing the phase advancing effects of one evening dose of exogenous melatonin, alone and in combination with one session of morning bright light exposure, in a randomized placebo-controlled double-blind circadian protocol. The effects of four conditions, dim light (~1.9 lux, ~0.6 Watts/m²)-placebo, dim light-melatonin (5 mg), bright light (~3000 lux, ~7 Watts/m²)-placebo, and bright light-melatonin on circadian phase was assessed by the change in the salivary dim light melatonin onset (DLMO) prior to and following treatment under constant routine conditions. Melatonin or placebo was administered 5.75 hours prior to habitual bedtime and 3 hours of bright light exposure started 1 hour prior to habitual wake time. It was obtained that morning bright light combined with early evening exogenous melatonin induced a greater phase advance of the DLMO than either treatment alone. Bright light alone and melatonin alone induced similar phase advances [REDACTED].

Morning injections of melatonin did not affect sleep parameters in young adults; however, peripheral hand temperature was reported to increase. Administration of both melatonin and temazepam at 1400 hour resulted in decreased sleep-onset latency in young people and concomitant changes in peripheral skin temperature measured at the feet. In that study, sleep-onset latency was assessed using the multiple sleep latency test, a well-established method of assessing sleep propensity during wake-time. Compared with placebo, melatonin reduced sleep-onset latency by 4.8 ± 1.49 min and temazepam (a benzodiazepine used to treat insomnia) reduced sleep latency by 6.5 ± 1.62 min. In this crossover, randomized, placebo-controlled study, the degree of change of sleep-onset latency was similar between the benzodiazepine and melatonin [REDACTED]. In an older population, Dawson and colleagues reported no changes in polysomnographic sleep following short-term melatonin administration via a transbuccal patch [REDACTED]. Longer treatment periods in the elderly (oral) did result in actigraphically-recorded improvements in sleep parameters, such as sleep efficiency and wake after sleep onset [REDACTED]. Furthermore, no cognitive impairment was reported in association with treatment of healthy middle aged and elderly individuals with prolonged release melatonin on the day after treatment [REDACTED].

Another study in healthy young adults demonstrated that melatonin significantly improved sleep efficiency, particularly during the time of the so-called wake maintenance zone or forbidden zone for sleep [REDACTED]. Melatonin administered in the late afternoon just prior to an advanced and extended sleep opportunity (1600 – 0800 hours), significantly increased the total amount of sleep obtained in the period 1600 – 2400 h by 2 h (3.37 h in controls vs 5.37 h in the melatonin-treated group) [REDACTED]. Thus, melatonin facilitated sleep when the sleep opportunity occurred at a biologically inappropriate time. Supporting these findings, a study of the efficacy of melatonin in healthy volunteers maintained in a forced desynchrony protocol reported that melatonin improved sleep efficiency when it was administered when endogenous melatonin levels are low, but not when endogenous levels are high [REDACTED].

In the study [REDACTED] both light and melatonin were used in order to determine whether phase advances induced by morning intermittent bright light and a gradually advancing sleep schedule

2.5 Clinical overview

could be increased with afternoon melatonin. There were significantly larger phase advances with 0.5 mg (2.5 hours, n = 16) and 3 mg melatonin (2.6 hours, n = 13), compared with placebo (1.7 hours, n = 15), but there was no difference between the two melatonin doses, although slightly larger phase shifts were obtained with the 3 mg dose.

Three different morning light patterns combined with a low dose of afternoon melatonin (0.5 mg) and a sleep/dark schedule that was advanced by 1 hour/day for 3 days have been also compared [REDACTED]. Despite different protocols, different melatonin doses, and different types of morning light among previous studies, the phase advancing effect of morning light alone and afternoon melatonin alone are roughly similar and when combined they are roughly additive. The authors tested these 3 different morning bright light patterns combined with a low dose of afternoon melatonin and a gradual advance of sleep/dark over three days to advance circadian rhythms. Such a strategy could be used to help night owls or people with DSPD, to help people adapt to an early work or school schedule, to help a shift worker who has to work early morning shifts, or help travellers to reduce or prevent jet lag. The 2-hour (30 minutes × 4) morning bright light exposure produced the largest phase advance; however, one 30-minute bright light exposure immediately upon waking each day is effective and takes a quarter of the time.

Melatonin capsules was administered to 21 students with sleep-onset insomnia, due to delay of circadian phase. Melatonin (1 mg) capsules or placebo was administered to subjects for three weeks. The study [REDACTED] showed that a small dose of melatonin, administered in the afternoon will result in a significant advanced sleep timing. The treatment was effective although the subjects continued with their often irregular sleep habits [REDACTED].

In a short-term pilot study, the sleep-promoting action of melatonin (3 mg p.o. for 6 months) was investigated in a small non-homogenous group of insomniac patients, under benzodiazepine treatment. Melatonin augmented significantly sleep quality, duration and decreased sleep latency and the number of awakening episodes. Overall, 20 out of 22 patients improved sleep at the end of treatment and estimates of next-day function. The observed effects lasted for the entire period examined [REDACTED].

The effectiveness of preoperative oral melatonin medication on sedation sleep quality was assessed [REDACTED]. patients received an oral placebo (n = 26) or 6 mg melatonin (n = 26) the night before and 1 hour before surgery and additionally all patients received a standard anaesthetic protocol. Extubation time and recovery time from anaesthesia were significantly longer in the melatonin group. Intraoperative fentanyl usage, pain scores and tramadol consumption were significantly better in the melatonin group than in the control group. The sedation scores were significantly higher in the melatonin group than in the control group at 1 hour and 2 hours after surgery. The authors concluded that patients had enhanced sleep quality during the postoperative period [REDACTED].

In a randomized, double-blind placebo-controlled study included 33 patients received either oral melatonin 5 mg (n = 17) or placebo (n = 16) the night before and 1 hour before surgery. The findings of the study suggested that preoperative melatonin produced clinically relevant anxiolytic and analgesic effects, especially in the first 24 postoperative hours. Melatonin also may accelerate the resynchronization of circadian rhythms in the postoperative period, suggesting better recovery quality which could be a consequence of melatonin's effects on pain and anxiety, which usually enhance rhythmicity disruption in stressful situations such as surgeries [REDACTED].

2.5 Clinical overview

2.5.4.5 DOSAGE AND ADMINISTRATION

The recommended dose in adults is 3 mg - 6 mg (3 ml of the proposed solution or 6 ml of solution) taken one hour before bedtime, for over 4 - 7 days. For the treatment of jet-lag, the initial dosing should be 6 mg on the first three days in the new time zone, followed by 3 mg taken one hour before bedtime. This is the same recommendation as in Bio-melatonin 3 mg tablets (Bio-Melatonin 3 mg filmtabletta), approved in Hungary (2003) [REDACTED].

The proposed dose has been used in a number of clinical trials, as presented in Sections 2.5.3 and 2.5.4.

Although various doses of melatonin have been used in clinical practice, typically between 1 mg and 10 mg, a 3 mg dose is one of the most commonly used dose for the treatment of jet-lag and other circadian rhythm sleep disorders.

According to the literature, daily doses up to 300 mg of melatonin do not produce any clinically significant side effects.

The safety and efficacy of melatonin in children aged 0 to 18 years has not been established.

The metabolism of melatonin decreases with the progression of age. However, no dosing recommendation can be made for the elderly, due to the significant differences in the pharmacokinetics of melatonin between individuals, even between those of the same sex.

Although, the effect of any stage of renal impairment on melatonin pharmacokinetics has not been studied. Caution should be used when melatonin is administered to such patients. Melatonin is not recommended for those with severe renal impairment.

There is no experience of the use of melatonin in patients with liver impairment. Published data demonstrates markedly elevated endogenous melatonin levels during daytime hours, due to decreased clearance in patients with hepatic impairment. Therefore, melatonin is not recommended for use in patients with hepatic impairment.

2.5.5 OVERVIEW OF SAFETY

In this section, the potential adverse effects after Melatonin administration are based on literature data. [REDACTED]

[REDACTED] The most common adverse reactions after oral administration of Melatonin are: headache, hyperactivity, dizziness, drowsiness, abdominal pain, nausea and diarrhoea.

2.5.5.1 TOXICITY

There is remarkably little published information regarding the potential adverse effects of melatonin administration. Melatonin appears to have a favourable adverse effect profile; headaches, dizziness, nausea, and drowsiness are the most common adverse events reported with short-term melatonin

2.5 Clinical overview

administration. Melatonin treatment appeared to be well tolerated in patients [REDACTED]. This result did not change by dose, the presence or absence of a sleep disorder, type of sleep disorder, duration of treatment, gender, age, formulation of melatonin, use of concurrent medication, study design, quality score, and allocation concealment score [REDACTED]. Fatigue occurs when melatonin is administered in the morning at higher doses (> 50 mg) [REDACTED]. Indeed, most studies with melatonin point out that overall adverse effects of melatonin are insignificant and, in general, similar to those found with placebo [REDACTED]. No hangover effects have been observed with melatonin when administered at reasonable concentrations, partially as a consequence of its short half-life.

2.5.5.1.1 Acute Toxicity

Melatonin and analogues appear to have extremely low acute toxicity. In rats and mice, oral doses of melatonin in excess of 1000 mg/kg are needed to induce death; the estimated doses required to cause death in 50 % of the animals treated (LD₅₀ values) are 1250 and 3200 mg/kg in mice and rats, respectively. 2-Iodomelatonin, which is at least 10-fold more potent than melatonin in affecting biological responses, caused death in a minority of animals even at the highest doses tested (800 mg/kg orally, 600 mg/kg by intraperitoneal injection) [REDACTED]. These doses are so far above the doses recommended for human consumption as to be nearly irrelevant (maximal intake in humans is approximately 5 mg/kg in women taking 300 mg/day). Acute administration of melatonin appears to have little consistent effect on hormone levels in adult humans. Several early studies indicated effects of melatonin on growth hormone secretion in men, whereas a more recent comprehensive study [REDACTED] indicated that the only acute effect of melatonin was an elevation in prolactin levels, as determined in 24 young healthy males after oral administration of 240 mg melatonin. If melatonin administered in sufficiently high doses, may well also enhance GH (Growth Hormone) levels, whereas various other hormones are not influenced [REDACTED].

Melatonin has been also used for its hypnotic, anti-nociceptive and anticonvulsant properties as an hypnotic anaesthetic agent. Antony-Tay and co-workers were the first to demonstrate clearly the orally administered 0.2 mg/kg melatonin produced loss of consciousness in human beings accompanied by a pattern of EEG activity similar to that seen during intravenous and volatile anaesthetic-induced loss of consciousness [REDACTED].

2.5.5.1.2 Long-term toxicity and Chronic Toxicity

The absence of detectable gross toxicity following several months of melatonin administration does not rule out significant adverse effects of the hormone. Some effects of melatonin administration may become apparent only after long latencies [REDACTED]. A relevant example is the development of osteoporosis, which occurs earlier, more frequently, and to a greater extent in women with premature removal of the ovaries (or premature menopause) than in controls.

Correlation between a developmental decline in melatonin levels with the timing of puberty in humans led to speculation that melatonin regulates the timing of puberty [REDACTED]. Subsequent investigation indicated that this developmental decline in melatonin levels is due at least in part to developmental changes in body mass (and thus volume of distribution) and is without a strict relationship to pubertal development [REDACTED], and references therein). Although endogenous melatonin does not appear to play a role in timing human puberty, no data are available to draw a conclusion with respect to the effects of exogenous melatonin on puberty in humans. These data indicate that the amplitude of nocturnal melatonin secretion does not have a role in the regulation of reproductive events in menstrual primates.

2.5 Clinical overview

Melatonin is used mostly for short term administration in cases of jet lag or shift work disorders. Thus, there is no effect on endogenous melatonin secretion. There are studies that confirm the safety of melatonin administration, even in long-term administration cases and no effect on endogenous melatonin secretion has been observed.

Chronic administration of melatonin also appears to be well tolerated. Women taking melatonin as a contraceptive agent ingest up to 300 mg melatonin daily; the initial report of this regimen indicated that no toxic effects were noted in the 4-month treatment period [REDACTED]. Alterations in hormone concentrations noted in this study are viewed as evidence of melatonin's efficacy rather than as an indication of toxicity. Other examples of chronic melatonin treatment at lower doses (e.g., 5 mg/day for hypnotic effect) have been reported without obvious evidence of adverse effects [REDACTED], however abnormally high (or pharmacologic) concentrations of melatonin in women are associated with altered ovarian function and anovulation.

2.5.5.1.3 Effect of administered melatonin on suppression of endogenous melatonin secretion

Melatonin is used mostly for short term administration in cases of jet lag or shift work disorders. Thus, there is no effect on endogenous melatonin secretion. There are studies that confirm the safety of melatonin administration, even in long-term administration cases and no effect on endogenous melatonin secretion has been reported.

It has been considered that endogenous melatonin was not modified by administration of D7 melatonin, as it was previously demonstrated that the amplitude of melatonin production is not affected by melatonin administration and that melatonin only has an influence on circadian timing when administered several hours before onset time [REDACTED]. [REDACTED] demonstrated that the low basal concentrations of melatonin in the blood are not affected by an increased melatonin supply up to a certain critical threshold, that the pineal gland would have to release all its melatonin content almost every 10 sec in order to sustain the elevated steady-state level of melatonin in the circulation during the dark period and that significant day/night differences exist in the disposition of circulating melatonin if administered in near physiological amounts and under near physiological conditions [REDACTED].

[REDACTED] measured the endogenous melatonin profiles after administration of a physiological dose of melatonin (0.5 mg) or placebo at bedtime to night shift workers (n = 21) for seven days. The amplitude of endogenous melatonin secretion was unchanged by treatment. Additionally, a melatonin treatment trial using a 50 mg daily bedtime dose for 37 days to a blind subject resulted in no change in the endogenous melatonin profile [REDACTED].

Exogenous melatonin did not affect the production of endogenous melatonin in terms of secretion rate, amplitude and duration also in the study [REDACTED]. The effects of an artificially prolonged melatonin (1.5 mg) profile on endogenous melatonin and cortisol rhythms, wrist actigraphy, and reproductive hormones in humans was investigated. Compared with placebo, melatonin administration advanced the timing of endogenous melatonin and cortisol rhythms. They concluded that melatonin treatment did not affect the endogenous melatonin profile duration, pituitary/gonadal hormone levels (24 h), or sleepiness and mood levels on the subsequent day [REDACTED].

2.5 Clinical overview

2.5.5.1.4 Effect of Melatonin on Cardiovascular System

The effect of 2 mg Melatonin or placebo on the Heart Rate Variability (HRV) of 26 healthy men was evaluated [REDACTED]. Compared with placebo, melatonin administration within 60 minutes increased R-R interval, the square root of the mean of the squared differences between adjacent normal R-R intervals, high-frequency power, and low-frequency power of HRV and decreased the low-frequency to high-frequency ratio and blood pressure in the supine position (all $P < 0.01$). Plasma norepinephrine and dopamine levels in the supine position 60 minutes after melatonin administration were lower compared with placebo ($P < 0.05$ and $P < 0.01$, respectively). Standing up resulted in the decrease of HRV and the increase of blood pressure and plasma catecholamine levels in both administration groups, and the differences between the groups found in the supine position disappeared. Melatonin administration also may exert suppressive effects on sympathetic tone [REDACTED].

2.5.5.1.5 Pre-implantation development

Limited evidence suggests that the contraceptive efficacy of melatonin in humans is due to effects on release of hypothalamic hormones rather than on uterine mechanisms, although effects on uterine "readiness for implantation" cannot be discounted. The uterus certainly is another tissue that should be examined when assessing the chronic effects of melatonin treatment in humans [REDACTED].

2.5.5.1.6 Mutagenicity

Assessment of melatonin and melatonin analogues or its major metabolites using the Ames test indicates that melatonin, 6-hydroxymelatonin and 2-iodomelatonin are devoid of mutagenic activity [REDACTED].

2.5.5.1.7 Pregnancy and Lactation

2.5.5.1.7.1 *Fertility*

Infertility treatments are associated with significant levels of reactive oxygen species which have the potential to negatively affect the quality of oocytes and embryos. Melatonin shows promise as an adjunctive therapy in the treatment of infertility. Its unique anti-oxidative characteristics and safety profile make it an ideal potential adjuvant therapy [REDACTED].

A recent phase II double blind placebo controlled randomised trial has shown that melatonin can help reduce chronic pelvic pain in women with endometriosis potentially through its effects on brain-derived neurotrophic factor and beneficial effects on sleep quality [REDACTED]. Level II evidence has also determined the effectiveness of melatonin as an analgesic in temporomandibular disorders [REDACTED] and as a method of reducing oxidative stress and improving dyspnoea in patients with chronic obstructive pulmonary disease [REDACTED]. Despite this, melatonin use in infertility treatment still lacks adequate evidence to recommend routine use.

2.5.5.1.7.2 *Pregnancy*

The role of melatonin in embryo foetal development has been recently reviewed [REDACTED]. Chronodisruption leads to reproductive dysfunction and appears to be a key contributor to offspring diseases that develop in adult life (the concept of foetal programming). Melatonin decreases in conditions associated with serious outcome for the foetus and seems to be involved in preeclampsia and intrauterine growth restriction [REDACTED]. Melatonin treatment during human normal or abnormal

2.5 Clinical overview

pregnancy has been studied for a large range of conditions and at different times during the gestational period. Considering the ethical issues, it is more difficult to study a normally occurring pregnancy, than an in vitro fertilization (IVF) one. Melatonin administration started prior to IVF-cycles, continued during pregnancy and was associated with improved pregnancy outcomes [REDACTED]. Melatonin receptors are widespread in the human foetus from early foetal development. In addition, it appears that the foetuses' sleep patterns develop in the late pregnancy, melatonin being the regulating factor. A normal sleep pattern is involved in the neurodevelopment and there is solid evidence that melatonin is involved in foetal neuroprotection [REDACTED]. Thus, the influence of melatonin on the developing human foetus may not be limited to entertaining the circadian rhythmicity.

Melatonin crosses the placenta and has been found to show rhythmic variations in milk, in parallel with plasma, in both humans and goats. Thus, it is highly likely, if taken by pregnant women, that the foetus will be exposed to excess melatonin, and the possibility exists that it will modify subsequent development in terms of the circadian system and the timing of puberty [REDACTED].

It has been suggested that exogenous melatonin increases GSH-Px activity in the chorion and thereby may protect indirectly against free radical injury and thus it could be useful in treating preeclampsia and possibly other clinical states involving excessive free radical production, such as intrauterine foetal growth retardation and foetal hypoxia [REDACTED].

[REDACTED] suggest that alterations in maternal or placental melatonin might alter foetal melatonin levels and thus gene expression in the foetal nervous system [REDACTED].

2.5.5.1.7.3 *Lactation*

Some authors suggest that mothers should nurse in the dark at night in order to avoid reductions in the melatonin content of breastmilk, which could disturb infant sleep patterns [REDACTED]. Differentiating milk pumped during the day from milk pumped during darkness has also been suggested for women expressing milk for their infants [REDACTED]. Some studies have attributed a longer sleep time in breastfed infants than in formula-fed infants due to melatonin in breastmilk [REDACTED]. Another study found higher colostrum melatonin levels at night which appeared to increase the phagocytic activity of colostrum cells against bacteria [REDACTED]. Exogenous administration of melatonin has no specific use during breastfeeding and no data exist on the safety of maternal use of melatonin during breastfeeding. However, doses higher than those expected in breastmilk after maternal supplementation have been used safely in infants [REDACTED]. It is unlikely that short-term use of usual doses of melatonin in the evening by a nursing mother would adversely affect her breastfed infant, although some authors recommend against its use in breastfeeding because of the lack of data and a relatively long half-life in preterm neonates [REDACTED].

In studies in which exogenous oral melatonin was given to women, the resulting serum melatonin was variable, but peak serum concentrations ranged from 1.1 to 2.6 mcg/L for each 1 mg administered [REDACTED]. This would result in an average increase in breastmilk melatonin concentration from 0.4 to 1 mcg/L for each 1 mg administered to the mother, based on an average milk concentration of 35 % of the maternal serum concentration. While the resulting concentrations would be higher than the typical physiologic peak milk concentrations of 0.02 mcg/L [REDACTED], it would present a considerably lower dose to the infant than the 10 mg/kg dosages of melatonin that have been safely administered to neonates in clinical studies [REDACTED]. It seems unlikely that prenatal melatonin exposure will strongly influence reproductive development in humans [REDACTED]. However, it seems unlikely that prenatal melatonin exposure will strongly influence reproductive development in humans [REDACTED].

2.5 Clinical overview

2.5.5.2 DRUG INTERACTIONS

2.5.5.2.1 Pharmacokinetic drug interactions

Caffeine has been shown to increase the oral bioavailability of melatonin, probably due to inhibition of CYP1A2-catalyzed first-pass metabolism of melatonin [REDACTED]. In addition, this effect was found to be more pronounced in non-smoking subjects and in subjects with the CYP1A2*1F/*1F genotype. In a study of five healthy male volunteers, 50 mg of oral fluvoxamine, a potent CYP1A2 inhibitor, was shown to substantially increase the bioavailability of oral melatonin with AUC and C_{max} values increasing 17 fold and 12 fold, respectively. Whereas the combined oral contraceptive resulted in a 4- to 5-fold increase in AUC and C_{max} compared to non-OC users (non-Oral Contraceptive users) [REDACTED].

Cimetidine increases plasma concentration of melatonin (via CYP1A2) by inhibiting metabolism of melatonin [REDACTED] which increases the levels of plasma melatonin.

The effect of melatonin on metabolic side effects of olanzapine was evaluated in a randomized double-blind placebo-controlled trial of 48 patients with first episode schizophrenia who were eligible for olanzapine treatment [REDACTED]. Patients were randomly assigned to olanzapine plus either melatonin 3 mg/day or matched placebo and were followed for 8 weeks. Metabolic parameters including weight, waist circumference, triglyceride, cholesterol, insulin, and blood sugar were assessed at baseline, week 4, and week 8. The study found that melatonin was associated with significantly less weight gain, increase in waist circumference and triglyceride than the placebo. Changes in cholesterol, insulin, and blood sugar did not differ significantly between the two groups.

CYP1A2 inhibitors (e.g. Quinolones) may increase the melatonin exposure and melatonin inhibits the antibacterial activity of ciprofloxacin [REDACTED]. The study [REDACTED] showed that the antibacterial activity of ciprofloxacin was inhibited by the pre-treatment of bacteria with antioxidant agents such as melatonin. This is likely to be related to the interference with induction of ROS by ciprofloxacin.

Results of a clinical study demonstrate that 8-methoxypsoralen (8-MOP or 5) intake is followed by correlated changes in melatonin levels and an independent decrease in serum aMT6s levels, suggesting a competitive inhibition of hepatic melatonin metabolism [REDACTED].

Melatonin down-regulates the circulating levels of gonadal oestrogens and acts as an antioestrogen with mechanisms of action different to those of the commercially available antioestrogens and inhibits aromatase expression in human breast cancer cells. The metabolism by CYP1A1 isoenzymes are inhibited and CYP1A2 increases melatonin levels [REDACTED]. Caution should be exercised in patients on oestrogens (e.g. contraceptive or hormone replacement therapy), which increase melatonin levels by inhibiting its metabolism by CYP1A1 CYP1A2 [REDACTED].

CYP1A2 inducers, such as carbamazepine and rifampicin may reduce melatonin plasma concentration [REDACTED].

Cigarette smoking may decrease melatonin levels due to induction of CYP1A2 [REDACTED]. [REDACTED] showed that exogenous, but not endogenous (at night), serum melatonin levels are influenced by cigarette smoking. When the melatonin levels are low, the influence of CYP1A2 levels appears to be less pronounced than when they are high and the enzyme capacity hugely utilized. These findings implicate that interactions between exogenous melatonin and substrates metabolized by CYP1A2 may differ in individuals before and after smoking abstinence [REDACTED].

2.5 Clinical overview

2.5.5.2.2 Pharmacodynamic drug interactions

In humans, co-administration of melatonin and zolpidem showed pharmacodynamic interaction (increased sedation) [REDACTED]. The effects of therapeutic oral doses of prolonged-release melatonin (2 mg) zolpidem (10 mg) and their combination administered at bedtime in cognitive functions in healthy subjects were assessed in a randomized, double-blind, placebo-controlled and four-way crossover study. A new pharmacodynamic between melatonin and zolpidem at 1 hour following co-dosing was observed, which was partly attenuated by 4 hours. Melatonin concentrations after administration of melatonin and melatonin + zolpidem were comparable with a peak at 1 – 2 hours. The same scheme was observed also for zolpidem concentration and thus a pharmacokinetic interaction can be discarded. Melatonin was not found associated with impairment of psychomotor functions, memory recall and driving skills and point to a pharmacodynamic interaction between melatonin and GABA-A modulators.

Concomitant administration of melatonin and drugs affect the CNS may result in pharmacodynamic drug interactions [REDACTED]. For example, relative to monotherapy with the CNS-active drug, patients receiving melatonin PR and imipramine had increased feelings of tranquillity and difficulty in performing tasks, and those receiving melatonin PR plus thioridazine had increased feelings of 'muzzy-headedness' [REDACTED]. Combination of melatonin and imipramine did not exert an antidepressant effect that of imipramine alone, co-administration of the effective dose displayed an additive effect and that there seems to be no interaction between the two compounds [REDACTED]. In the study of [REDACTED], AD patients with sleep disturbances were treated with melatonin 3 mg capsules for 21 days. Patients who received 25 mg/ day thioridazine because of their behavioural and sleep disorder interrupted thioridazine treatment after 5 and 24 months of starting melatonin treatment, respectively [REDACTED].

Alcohol should not be taken with melatonin, because it reduces the effectiveness of melatonin on sleep [REDACTED].

2.5.6 BENEFITS AND RISKS CONCLUSIONS

2.5.6.1 THERAPEUTIC CONTEXT

2.5.6.1.1 Disease or Condition

Melatonin, as a neurohormone that is primarily produced in the pineal gland, can acutely attenuate the activity of the SCN. This melatonin action is likely to support a normal decline in the activity of the SCN at night, further promoting melatonin secretion and contributing to an overall increase in the amplitude of circadian body rhythms. Melatonin has a proven effectiveness in sleep-wake disorders and especially in jet lag disorder and shift work disorder, although the hormone contributes also to the protection of the organism from carcinogenesis and neurodegenerative disorders. The planned medicinal product will be available as oral solution of 3 mg Melatonin.

2.5.6.1.2 Current Therapies

Current therapies of jet lag and shift work disorder include light therapy, melatonin, melatonin receptor analogues [Ramelteon (Rozerem©, Takeda, Japan; TAK-375), Agomelatine (Valdoxan©, Servier, France; S20098), TIK-301, Tasimelteon (Hetlioz, Vanda Pharmaceuticals, USA)], non-benzodiazepine hypnotics, caffeine, diphenhydramine and CNS stimulants such as armodafinil. The

2.5 Clinical overview

patient's flight schedule, physical condition and individual response to treatment play important roles. Benzodiazepines, antidepressants, antihistamines and anxiolytics have the potential for dependence and addiction. Moreover, some of these medications can gradually impair cognition.

Administering exogenous melatonin in the conventional afternoon to evening hours of a 24-hour day promotes a phase shift in circadian rhythm and thus promoting sleep.

[REDACTED]

2.5.6.2 BENEFITS

Melatonin is remarkably effective in preventing or reducing jet lag and has been the subject of many studies. When making travel plans, particularly over a distance of five or more time zones, travelers should take melatonin on the day of travel at the projected night time hour in the new time zone and on subsequent days in the new time zone. The impact of various dosage forms of melatonin on jet lag symptoms has been evaluated in several studies.

Most of the clinical trials included in the clinical overview [REDACTED] found that melatonin taken close to the target bedtime at the destination (10 pm to midnight), decreased jet lag from flights crossing five or more time zone. The benefit is likely to be greater the more time zones are crossed and less for westward flights. The timing of the melatonin dose is important: if is taken at the wrong time, early in the day, it is liable to cause sleepiness and delay adaptation to local time.

Melatonin is additionally effective in workers who undertake shift work, including night shifts and who may or may not have sleep problems. Melatonin can increase sleep length during daytime sleep and night time sleep after the night shift and improves sleep quality parameters.

2.5.6.3 RISKS

Melatonin is well tolerated with a good safety profile, with most adverse events being of mild severity. Headaches, dizziness nausea and drowsiness are the most common adverse events reported with short term melatonin administration. [REDACTED]

[REDACTED] The number of adverse events in most of the clinical studies do not differ significantly between melatonin and placebo groups and none of the adverse events require treatment.

[REDACTED]

In all cases there was no significant differences found between melatonin and placebo despite tight confidence intervals.

The risk of overdose is low and does not change by dose, the presence or absence of a sleep disorder, type of sleep disorder, duration of treatment, gender, age, formulation of melatonin, use of concurrent medication, study design, quality score and allocation concealment score. Melatonin interacts only with few other active substances.

2.5 Clinical overview

2.5.6.4 BENEFIT – RISK ASSESSMENT

Melatonin is a neurohormone that is primarily produced in the pineal gland, located behind the third ventricle in the brain with daily and seasonal rhythms mainly under the control of the circadian oscillator located in the suprachiasmatic nuclei of the hypothalamus (SCN) which have melatonin receptors. It is synthesized in the pineal gland during the dark phase of the light/dark cycle, rapidly delivered to the body via the systemic circulation and involved in the entrainment (synchronization) of the circadian rhythms including sleep-wake timing, blood pressure regulation, seasonal reproduction, and many others.

Jet lag commonly affects air travellers who cross several time zones and results from the body's internal rhythms being out of step with the day-night cycle at the destination. Melatonin may help shift workers by either by reducing sleepiness and improving alertness during work-shifts, or by reducing sleep disturbances while off work. In this case there are two categories of drugs, substances to help shift workers prevent drowsiness or improve alertness during shift work, or substances to improve sleep quality or sleep length after a shift work period.

There are two general approaches to address the symptoms of jet lag and shift work disorder. The first is to accelerate realignment of the circadian system with the external environment and the second is to treat the symptoms of insomnia and excessive sleepiness. Multimodal approaches are typically needed and should be tailored to the individual, because the severity of symptoms and timing of treatments depends on the direction of travel and number of times zones crossed or the type of work schedule.

Exogenous Melatonin has been extensively studied about its absorption and bioavailability in humans. Melatonin is rapidly absorbed following oral administration of instant release forms, with T_{max} ranging between 0.25 - 1.0 hours and a $T_{1/2}$ as low as 6 minutes.

Melatonin's utility in the management of jet lag and shift work disorder has been the subject of many studies and the advantages of melatonin in relation to other sleep-inducing agents are the absence of hangover the morning after, the absence of withdrawal symptoms and the absence of addiction.

Based on extensive analysis of literature data, it can be stated that the therapeutic benefit clearly outweighs the possible risk associated with the use of melatonin as recommended by the applicant.

[REDACTED]

■ [REDACTED]
[REDACTED]
[REDACTED]

■ [REDACTED]
[REDACTED]
[REDACTED]

■ [REDACTED]
[REDACTED]
[REDACTED]

2.5 Clinical overview

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

2.5 Clinical overview

- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]
- [Redacted]

2.5 Clinical overview

- [Redacted text]
- [Redacted text]
- [Redacted text]
- [Redacted text]
- [Redacted text]
- [Redacted text]
- [Redacted text]
- [Redacted text]
- [Redacted text]
- [Redacted text]
- [Redacted text]
- [Redacted text]
- [Redacted text]
- [Redacted text]
- [Redacted text]

2.5 Clinical overview

88, [REDACTED]
[REDACTED]
[REDACTED]

[REDACTED] [REDACTED]
[REDACTED]
[REDACTED]

[REDACTED] [REDACTED]
[REDACTED]

[REDACTED] [REDACTED]
[REDACTED]

[REDACTED] [REDACTED]
[REDACTED]

[REDACTED] [REDACTED]
[REDACTED]

[REDACTED] [REDACTED]
[REDACTED]
[REDACTED]

[REDACTED] [REDACTED]
[REDACTED]
[REDACTED]

[REDACTED] [REDACTED]
[REDACTED]
[REDACTED]

[REDACTED] [REDACTED]
[REDACTED]
[REDACTED]

[REDACTED] [REDACTED]
[REDACTED]
[REDACTED]

[REDACTED] [REDACTED]
[REDACTED]
[REDACTED]

[REDACTED] [REDACTED]
[REDACTED]
[REDACTED]

[REDACTED] [REDACTED]
[REDACTED]
[REDACTED]

[REDACTED] [REDACTED]
[REDACTED]
[REDACTED]

[REDACTED] [REDACTED]
[REDACTED]
[REDACTED]

[REDACTED] [REDACTED]
[REDACTED]
[REDACTED]

2.5 Clinical overview

[Redacted text block containing multiple paragraphs of clinical overview information, all obscured by black bars.]

2.5 Clinical overview

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

2.5 Clinical overview

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

2.5 Clinical overview

[Redacted text block containing multiple paragraphs of clinical overview information, all content obscured by black bars.]

2.5 Clinical overview

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

2.5 Clinical overview

█ [REDACTED]
[REDACTED]
[REDACTED]

█ [REDACTED]
[REDACTED]
[REDACTED]

█ [REDACTED]
[REDACTED]
[REDACTED]

█ [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

█ [REDACTED]
[REDACTED]
[REDACTED]
█ [REDACTED]

█ [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

█ [REDACTED]
[REDACTED]

█ [REDACTED]
[REDACTED]

█ [REDACTED]
[REDACTED]
[REDACTED]

█ [REDACTED]
[REDACTED]
[REDACTED]

█ [REDACTED]
[REDACTED]
[REDACTED]

█ [REDACTED]
[REDACTED]

█ [REDACTED]
[REDACTED]

2.5 Clinical overview

[Redacted text block containing approximately 15 lines of obscured content]

2.5 Clinical overview

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

2.5 Clinical overview

[REDACTED]